U.S. Department of Health and Human Services Office of the National Coordinator for Health Information Technology



Newborn Screening Detailed Use Case Coding and Terminology Guide December 19, 2008



Table of Contents

| Preface | 2 |
|--|----|
| Conditions | 4 |
| Analytes | 12 |
| MS/MS Analytes | 21 |
| (by molecular weight) | |
| MS/MS Analytes | 27 |
| (by molecular weight with calculated sums and ratios listed seperatly) | |
| MS/MS Condition to Analyte Mapping | 33 |
| MS/MS Analyte to Condition Mapping | 44 |



Preface

The Personalized Healthcare Workgroup developed a Newborn Screening Coding and Terminology Guide of condition and analyte terminology, codes, and mapping that is provided as a supplement to the use case for the purpose of facilitating development of electronic laboratory reports for newborn screening. Newborn screening is different form other laboratory testing in that results are often reported as screening positive or negative for a condition rather than reporting the quantitative results of the actual test performed. One of the newborn screening recommendations that was approved by the AHIC was to report both the clinical conditions identified and the quantitative analytes measured on the electronic reports so that they can support both patient focused care and population health activities. The attached matrix also bring together a variety of coding systems that may be required for rare disorders genetic disorders and provides LOINC codes to assist in identifying results included in a newborn screening report and documenting the methods used in the laboratory. Newborn dried blood spot screening is usually ordered as a single test or panel and the conditions screened for and the analytes that are measured and the methods of measurement may vary from state to state and over time.

This guide can be used to clearly document and encode the reports to identify the conditions screened for or identified and the test results that are associated those conditions. Maintenance of the newborn screening guide and codes will be an on-going activity as the field of newborn screening changes. The guide will also be used to store genotype information that is associated with specific phenotypes are identified by screening. This activity is just beginning and is not yet included in this version of the matrix, but it will become more important as direct genotype measures are among the results measured by newborn screening tests.

The reports that follow are a work in progress that will continue to evolve with additional input from programs and laboratories that perform newborn screening tests. These reports illustrate the types of coding and terminology that will be available for use in electronic newborn screening reports developed using the harmonized standards that will be selected for implementing the use case. Use of a standard framework for coding and terminology will assist in the comparison of data from different laboratories and help identify gaps in coding that should be addressed before laboratories begin to transmit electronic newborn screening reports. The current set of reports address only the initial screening tests carried out on newborn dried blood spots and by early hearing detection and intervention programs.

Many of the reports refer to ACMG primary, secondary, and other conditions that were defined in a report, Toward a Uniform Screening Panel and System¹, that identified 29 conditions for which screening should be mandated based on criteria scores and evaluation by experts. Additional

A LAND A LAND

conditions were identified for which the cost-effectiveness was less clear as well as other conditions that have a role in the differential diagnosis of a condition in the core panel.

The large number of synonyms for newborn screening conditions reflect the evolving state of scientific knowledge resulting in some conditions named by their clinical syndrome, enzyme deficiency, abnormal analyte measured, or specific genome alterations. The paper, Naming and Counting Disorders (Conditions) Included in Newborn Screening Panels² helps to elucidate this process and facilitated development of this guide. The use of ACMG codes has provided an effective unifying framework because they have been used as the basis for decisions on which tests to include in screening programs, and are the basis for the National Newborn Screening and Genetics Resource Center (NNSGRC) that have been harmonized³ in this guide. Clinical coding systems such as SNOMED and ICD10 do not always provide the necessary granularity in this rapidly evolving field and the National Library of Medicine's Unified Medical Language System (UMLS) is expected to assist this process of on-going mapping of variant terminologies and codes used in newborn screening.

¹Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR [editors]. (2006) Newborn screening: Toward a uniform screening panel and system [Executive summary]. Genet Med 8(Supplement):1S-11S.

²Sweetman L, Millington DS, Therrell BL, Hannon WH, Popovich B, Watson MS, Mann MY, Michele A. Lloyd-Puryear MA, van Dyck PC. Naming and Counting Disorders (Conditions) Included in Newborn Screening Panels. Pediatrics 2006;117;308-314.

³http://genes-r-us.uthscsa.edu/

Conditions

The Conditions report lists the conditions that can be identified by newborn screening tests along with appropriate diagnostic codes. The report includes conditions that are tested for by tandem mass spectrometry (MS/MS) on newborn dried blood spots, and conditions indentified by non-tandem mass spectrometry tests performed on newborn dried blood spots, as well as hearing loss detected through early hearing detection and intervention (EHDI) programs. Specific genetic causes of hearing loss and further classification of types of hearing loss are described in separate reports as this information is not obtained as a result of the newborn screening tests and this report is limited to initial newborn screening tests.

TBD - 'To be determined' in reference to ICD-10 codes highlights those conditions that still need to be classified.

N/A - 'Non applicable'

EHDI: Congenital Hearing Loss: Hearing Loss

| Condition [Enzyme] | ACMG | MIM | ENZYME | SNOMED | ICD10 |
|--------------------|------|------|--------|----------|--------|
| | Code | Code | Code | Code | Code |
| Hearing Loss | HEAR | N/A | N/A | 15188001 | H91.93 |

MS/MS: ACMG Primary Targets: Amino Acids

| Condition [Enzyme] | ACMG Code | MIM Code | ENZYME Code | SNOMED Code | ICD10 Code |
|---|--------------|-------------|----------------|----------------|---------------|
| Argininosuccinic aciduria [Argininosuccinate lyase] | ASA | 207900 | 4.3.2.1 | 41013004 | E72.22 |
| Citrullinemia type I [Argininosuccinate synthetase] | CIT I | 215700 | 6.3.4.5 | 398680004 | E72.21 |
| Homocystinuria [Cystathionine beta-synthase] | HCY | 236200 | 4.2.1.22 | 11282001 | E72.11 |
| Maple syrup urine disease [Branched-chain alpha-keto acid dehydrogenase] | MSUD | 248600 | 1.2.4.4 | 27718001 | E71.0 |
| Phenylketonuria [Phenylalanine hydroxylase] | PKU | 261600 | 1.14.16.1 | 7573000 | E70.0 |
| Tyrosinemia type I [Fumarylacetoacetate hydrolase] | TYRI | 276700 | 3.7.1.2 | 410056006 | E70.21 |

MS/MS: ACMG Primary Targets: Fatty Acid Oxidase

| Condition [Enzyme] | ACMG | MIM | ENZYME | SNOMED | ICD10 |
|--|------|--------|--------|----------|-------|
| | Code | Code | Code | Code | Code |
| Carnitine uptake defect [Plasma membrane carnitine transporter] | CUD | 212140 | | 21764004 | TBD |

| Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency [Long-chain L-3-Hydroxy dehydrogenase] | LCHAD | 609016 | 1.1.1.211 | 237999008 | E71.310 |
|--|-------|--------|-----------|-----------|---------|
| Medium-chain acyl-CoA dehydrogenase deficiency [Medium-chain acyl-CoA dehydrogenase] | MCAD | 607008 | 1.3.99.3 | 128596003 | E71.311 |
| Trifunctional protein deficiency [Trifunctional protein (alpha, beta subunit)] | TFP | 609015 | 1.1.1.211 | 237999008 | TBD |
| Very long-chain acyl-CoA dehydrogenase deficiency [Very long-chain acyl-CoA dehydrogenase] | VLCAD | 201475 | 1.3.99.13 | 237997005 | E71.310 |

MS/MS: ACMG Primary Targets: Organic Acids

| Condition [Enzyme] | ACMG Code | MIM Code | ENZYME Code | SNOMED Code | ICD10 Code |
|---|--------------|-------------|-------------------|----------------|---------------|
| 3-Hydroxy-3-methylglutaric aciduria [3-Hydroxy-3-methylglutaryl-CoA lyase] | HMG | 300438 | 4.1.3.4 | 124611007 | TBD |
| 3-Methylcrotonyl-CoA carboxylase deficiency [3-Methylcrotonyl-CoA carboxylase (alpha, beta subunit)] | 3MCC | 210200 | 6.4.1.4 | 13144005 | TBD |
| beta-Ketothiolase deficiency [beta-ketothiolase] | ВКТ | 203750 | 2.3.1.16, 2.3.1.9 | 124265004 | TBD |
| Glutaric acidemia type I [Glutaryl-CoA deydrogenase] | GA I | 231670 | 1.3.99.7 | 76175005 | E72.3 |
| Isovaleric acidemia [Isovaleryl-CoA dehydrogenase] | IVA | 243500 | 1.3.99.10 | 87827003 | E71.110 |
| Methylmalonic acidemia [Methylmalonyl-CoA mutase] | MUT | | 5.4.99.2 | 42393006 | E71.120 |
| Methylmalonic acidemia [Adenosylcobalamin synthesis] | CBL A | 251100 | 5.4.99.2 | 73843004 | E71.120 |
| Methylmalonic acidemia [Adenosylcobalamin synthesis] | CBL B | 251110 | 5.4.99.2 | 82245003 | E71.120 |
| Multiple carboxylase deficiency [Holocarboxylase synthetase] | MCD | 253270 | 6.3.4.11 | 15307001 | D81.81 |
| Propionic acidemia [Propionyl-CoA carboxylase] | PROP | 606054 | 6.4.1.3 | 69080001 | E71.121 |

MS/MS: ACMG Secondary Conditions: Amino Acids

| Condition [Enzyme] | ACMG Code | MIM Code | ENZYME Code | SNOMED Code | ICD10 Code |
|---|--------------|-------------|----------------|----------------|---------------|
| Argininemia [Arginase] | ARG | 207800 | 3.5.3.1 | 23501004 | E72.21 |
| Citrullinemia type II [Aspartate glutamate carrier (citrin)] | CIT II | 605814 | | 30529005 | E72.23 |



| Disorders of biopterin biosynthesis [6-Pyruvoyltetrahydropterin synthase] | BIOPT-BIO | 261640 | 4.2.3.12 | | TBD |
|--|-----------|--------|------------|-----------|--------|
| Disorders of biopterin regeneration [Dihydropteridine reductase] | BIOPT-REG | 261630 | 1.5.1.34 | 58256000 | TBD |
| Hypermethioninemia [Methionine adenosyltransferase] | MET | 250850 | 2.5.1.6 | 37695001 | E72.1 |
| Hyperphenylalaninemia (variant, benign) [Phenylalanine hydroxylase] | H-PHE | | 1.14.16.1 | 68528007 | E70.1 |
| Tyrosinemia type II [Tyrosine transaminase] | TYR II | 276600 | 2.6.1.5 | 4887000 | E70.21 |
| Tyrosinemia type III [4-Hydroxyphenylpyruvate acid oxidase] | TYR III | 276710 | 1.13.11.27 | 415764005 | E70.21 |

MS/MS: ACMG Secondary Conditions: Fatty Acid Oxidase

| Condition [Enzyme] | ACMG Code | MIM Code | ENZYME Code | SNOMED Code | ICD10 Code |
|---|--------------|-------------|----------------|----------------|---------------|
| 2,4-Dienoyl-CoA reductase deficiency [2,4-Dienoyl-CoA reductase] | DE RED | 222745 | 1.3.1.34 | | TBD |
| Carnitine palmitoyltransferase I deficiency [Carnitine palmitoyltransferase Ia] | CPT I | 255120 | 2.3.1.21 | 238001003 | E71.314 |
| Carnitine palmitoyltransferase II deficiency [Carnitine palmitoyltransferase II] | CPT II | | 2.3.1.21 | 124265004 | E71.314 |
| Carnitine-acylcarnitine translocase deficiency [Carnitine acylcarnitine translocase] | CACT | 255110 | 2.3.1.21 | 238003000 | E71.312 |
| Glutaric acidemia type II [Electron transfer flavoprotein [ETF] (alpha, beta subunit)] | GA II | 608053 | 1.5.5.1 | 22886006 | E71.313 |
| Medium-chain ketoacyl-CoA thiolase deficiency [Medium-chain ketoacyl-CoA thiolase] | MCKAT | 602199 | 2.3.1.16 | | TBD |
| Short-chain acyl-CoA dehydrogenase deficiency [Short-chain acyl-CoA dehydrogenase] | SCAD | 201470 | 1.3.99.2 | 124166007 | E71.312 |
| Short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency [Short-chain L-3-hydroxy acyl-CoA dehydrogenase] | SCHAD | 601609 | 1.1.1.35 | 237998000 | E71.312 |

MS/MS: ACMG Secondary Conditions: Organic Acids

| Condition [Enzyme] | ACMG Code | MIM Code | ENZYME Code | SNOMED Code | ICD10 Code |
|---|--------------|-------------|----------------|----------------|---------------|
| 2-Methyl-3-hydroxybutyric aciduria [2-Methyl-3-hydroxybutyryl-CoA dehydrogenase] | 2M3HBA | 300438 | 1.1.1.178 | | TBD |
| 2-Methylbutyrylglycinuria [2-Methylbutyryl-CoA dehydrogenase] | 2MBG | 610006 | 1.3.99.12 | | TBD |



| 3-Methylglutaconic aciduria [3-Methylglutaconyl-CoA hydratase] | 3MGA | 250950 | 4.2.18 | 237950009 | E71.111 |
|---|-------|--------|-----------|-----------|---------|
| Isobutyrylglycinuria [Isobutyryl-CoA dehydrogenase] | IBD | 604773 | 1.1.1.157 | | TBD |
| Malonic acidemia [Malonyl-CoA decarboxylase] | MAL | 248360 | 4.1.1.9 | 361203007 | TBD |
| Methylmalonic aciduria and homocystinuria [MMA mutase and homocysteine: MTHF methyl transferase] | CBL C | 277400 | 5.4.99.2 | 74653006 | E71.1 |
| Methylmalonic aciduria and homocystinuria [MMADHC protein] | CBL D | 277410 | | 31220004 | TBD |

MS/MS: Other Conditions: Amino Acids

| Condition [Enzyme] | ACMG Code | MIM Code | ENZYME Code | SNOMED Code | ICD10 Code |
|--|--------------|-------------|----------------|----------------|---------------|
| Carbamoyltransferase deficiency [Carbamoyltransferase I] | CPS | 237300 | | 124380007 | TBD |
| Girate atrophy of the retina [Ornithine aminotransferase] | Hyper ORN | 258870 | | 314467007 | H31.23 |
| Histidinemia [Histidine ammonia-lyase] | HIS | 235800 | | 410058007 | E70.41 |
| Homocystinuria-megaloblastic anemia [Methyltetrahydrofolate homocysteine methyltransferase] | CBL G | 250940 | | 360373000 | E72.11 |
| Hydroxyprolinemia [4-Hydroxy L-proline oxidase] | OH PRO | 237000 | | 25739007 | E72.59 |
| Hyperlysinemia [Lysine:alpha-ketoglutarate reductase] | Hyper LYS | 238700 | | 58558003 | E72.3 |
| Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome [Ornithine translocase] | ННН | 238970 | | 30287008 | TBD |
| Methylcobalamin deficiency [Methylcobalamin] | CBL E | 236270 | | 4409006 | TBD |
| Methylene tetrahydrofolate reductase deficiency [5,10-methylene tetrahydrofolate reductase] | MTHFR | 607093 | | 79514008 | E72.12 |
| Nonketotic hyperglycinemia (glycine encephalopathy) [Glycine cleavage system H protein] | NKHG | 605899 | | 237939006 | E72.51 |
| Ornithine transcarbamylase deficiency [Ornithine transcarbamylase] | отс | 300461 | | 80908008 | E72.4 |
| Pyroglutamic acidemia [Glutathione synthetase] | OXO PRO | 266130 | | 39112005 | TBD |
| Pyruvate carboxylase deficiency [Pyruvate carboxylase] | PC | 266150 | | 87694001 | E74.4 |

| Valinemia [Valine transaminase] | Hyper VAL | 277100 | | 47719001 | E71.19 | |
|------------------------------------|-----------|--------|--|----------|--------|--|
|------------------------------------|-----------|--------|--|----------|--------|--|

MS/MS: Other Conditions: Fatty Acid Oxidase

| Condition [Enzyme] | ACMG | MIM | ENZYME | SNOMED | ICD10 |
|---|-----------|--------|--------|----------|-------|
| | Code | Code | Code | Code | Code |
| Maternal carnitine uptake defect [Plasma membrane carnitine transporter] | CUD (mat) | 212140 | | 21764004 | TBD |

MS/MS: Other Conditions: Organic Acids

| Condition [Enzyme] | ACMG Code | MIM Code | ENZYME Code | SNOMED Code | ICD10 Code |
|--|--------------|-------------|----------------|----------------|---------------|
| Ethylmalonic encephalopathy [Unknown] | EE | 602473 | 1.5.5.1 | 193051008 | TBD |
| Formiminoglutamic acidemia [Glutamate formiminotransferase] | FIGLU | 229100 | | | TBD |
| Maternal 3-Methylcrotonyl-CoA carboxylase deficiency [3-Methylcrotonyl-CoA carboxylase (alpha, beta subunit)] | 3MCC (mat) | | 6.4.1.4 | 13144005 | TBD |
| Maternal glutaric acidemia type I [Glutaryl-CoA deydrogenase] | GA I (mat) | 231670 | 1.3.99.7 | 76175005 | TBD |
| Primary lactic acidemia (various types) [various enzymes] | LACTIC | | | 190882007 | E87.2 |
| Succinyl-CoA ligase deficiency [Succinyl-CoA ligase, beta-subunit] | SUCLA2 | 603921 | | 83792009 | TBD |

Non-MS/MS: Cystic Fibrosis:

| Condition [Enzyme] | ACMG | MIM | ENZYME | SNOMED | ICD10 |
|--------------------|------|--------|--------|-----------|-------|
| | Code | Code | Code | Code | Code |
| Cystic fibrosis | CF | 602421 | N/A | 190905008 | E84.9 |

Non-MS/MS: Endocrine Disorders:

| Condition [Enzyme] | ACMG Code | MIM Code | ENZYME Code | SNOMED Code | ICD10 Code |
|---|--------------|-------------|----------------|----------------|---------------|
| Congenital Adrenal Hyperplasia (non-classical) [Steroid 21-hydroxylase deficiency] | CAH | 201910 | 1.14.99.10 | 237752007 | E25.0 |
| Congenital Adrenal Hyperplasia (salt-wasting) [Steroid 21-hydroxylase deficiency] | САН | 201910 | 1.14.99.10 | 71578002 | E25.0 |
| Congenital Adrenal Hyperplasia (simple virilizing) [Steroid 21-hydroxylase deficiency] | САН | 201910 | 1.14.99.10 | 52604008 | E25.0 |

| Congential Adrenal Hyperplasia [Steroid 11-beta hydroxylase deficiency] | САН | 202010 | 1.14.15.4 | 237751000 | E25.0 |
|--|-----|--------|-----------|-----------|-------|
| | | | | | |

Non-MS/MS: Endocrine Disorders:

| Condition [Enzyme] | ACMG Code | MIM Code | ENZYME Code | SNOMED Code | ICD10 Code |
|-------------------------------------|--------------|-------------|----------------|----------------|---------------|
| Congenital Hypothyroidism | СН | N/A | N/A | 217710005 | E03.1 |
| Secondary Congenital Hypothyroidism | 20CH | N/A | N/A | 267376007 | E03.1 |
| Thyroid-Binding Globulin Deficiency | TBG | 314200 | N/A | 237544006 | E07.89 |

Non-MS/MS: Hemoglobin Disorders:

| Condition [Enzyme] | ACMG Code | MIM Code | ENZYME Code | SNOMED Code | ICD10 Code |
|-----------------------------|--------------|-------------|----------------|----------------|---------------|
| Hb C Beta-thalassemia | C/Beta-thal | N/A | N/A | | TBD |
| Hb D Beta-thalassemia | D/Beta-thal | N/A | N/A | | TBD |
| Hb E Beta-thalassemia | E/Beta-thal | N/A | N/A | | TBD |
| Hb H Disease | Hb H | N/A | N/A | 48553001 | TBD |
| Hb S Other | N/A | N/A | N/A | | TBD |
| Hemoglobin Disease Other | N/A | N/A | N/A | | TBD |
| Homozygous Beta-thalassemia | F only | N/A | N/A | 26682008 | D56.2 |
| Homozygous C Disease | FC | N/A | N/A | 51053007 | D57.2 |
| Homozygous E Disease | FE | N/A | N/A | 25065001 | D57.8 |
| S/Beta-thalassemia | S/Beta-thal | N/A | N/A | 79592006 | D57.4 |
| Sickle C-Disease | S/C | N/A | N/A | 35434009 | D57.2 |
| Sickle cell anemia | S/S | N/A | N/A | 191195005 | D57.1 |



| Sickle D Disease | S/D | N/A | N/A | 25472008 | D58.2 |
|-----------------------|----------|-----|-----|-----------|-------|
| Sickle E Disease | S/E | N/A | N/A | 47024008 | D58.2 |
| Sickle O-Arab Disease | S/O Arab | N/A | N/A | 127048005 | D58.2 |

Non-MS/MS: Hemoglobin Disorders:

| Condition [Enzyme] | ACMG Code | MIM Code | ENZYME Code | SNOMED Code | ICD10 Code |
|--------------------|--------------|-------------|----------------|----------------|---------------|
| FA + Other | N/A | N/A | N/A | | TBD |
| FAC | N/A | N/A | N/A | 76050008 | TBD |
| FAD/FAG | N/A | N/A | N/A | | TBD |
| FAE | N/A | N/A | N/A | 46248003 | TBD |
| FAS | N/A | N/A | N/A | | TBD |

Non-MS/MS: Infectious Diseases:

| Condition [Enzyme] | ACMG Code | MIM Code | ENZYME Code | SNOMED Code | ICD10 Code |
|------------------------------|--------------|-------------|----------------|----------------|---------------|
| Congenital toxoplasmosis | тохо | N/A | N/A | 73893000 | P37.1 |
| Human immunodeficiency virus | HIV | N/A | N/A | 187438009 | B20-B24 |

Non-MS/MS: Other Disorders:

| Condition [Enzyme] | ACMG | MIM | ENZYME | SNOMED | ICD10 |
|--------------------------|------|--------|--------|---------|---------|
| | Code | Code | Code | Code | Code |
| Biotinidase Deficiency 2 | BIO | 609019 | N/A | 8808004 | D81.810 |

Non-MS/MS: Other Disorders:

| Condition [Enzyme] | ACMG | MIM | ENZYME | SNOMED | ICD10 |
|---|------|--------|----------|-----------|--------|
| | Code | Code | Code | Code | Code |
| Classical galactosemia (galactose-1-phosphate uridyltransferase deficiency) | GALT | 230400 | 2.7.7.12 | 398664009 | E74.21 |



| Galactoepimerase deficiency (uridine diphosphate galactose 4-epimerase deficiency) | GALE | 230350 | 5.1.3.2 | 8849004 | E74.2 |
|--|------|--------|---------|-----------|--------|
| Galactokinase deficiency | GALK | 230200 | 2.7.1.6 | 124302001 | E74.29 |

Analytes

The Analytes report lists the analytes or chemical entities that are measured by newborn screening tests along with appropriate LOINC codes that are used to identify specific laboratory result fields on electronic laboratory reports. The report includes conditions that are tested for by tandem mass spectrometry (MS/MS) on newborn dried blood spots, and conditions indentified by non-tandem mass spectrometry tests performed on newborn dried blood spots, as well as hearing loss detected through early hearing detection and intervention (EHDI) programs. This report is limited to the initial newborn screening tests and does include additional measures used for confirmatory testing. Because LOINC codes will have separate values based on methods of testing or units of reporting, there may be more than one analyte entry for the same type of measurement. Analytes also include entries for computed sums and ratios when these values are included on the laboratory reports and have been assigned their own LOINC code to identify the result field. To assist in the use of this report, the MS/MS Analytes are listed in alphabetical order within categories and are also listed in molecular weight order which is the order in which they appear on the laboratory instrumentation. Computed sums and ratios are listed separately and also listed following the primary measurement on which they are based.

TBD - 'To be determined' in reference to LOINC codes highlights those analytes for which LOINC codes are being discussed or under development.

EHDI: Hearing Loss

| Analyte | Short Name | LOINC Code | Units |
|--|------------|------------|------------------|
| Auditory evoked potentials for screening | AEP | TBD | Pass or Refer |
| Evoked otoacoustic emissions for screening | EOE | TBD | Pass or Refer |

MS/MS: Amino Acids

| Analyte | Short Name | LOINC Code | Units |
|-------------------|------------|------------|--------|
| Arginine | ARG | 47562-4 | µmol/L |
| Argininosuccinate | ASA | 53062-6 | µmol/L |
| Aspartate | ASP | 47573-1 | µmol/L |
| Citrulline | СІТ | 42892-0 | µmol/L |
| Glutamate | GLU | 47623-4 | µmol/L |
| Glycine | GLY | 47633-3 | µmol/L |
| Histidine | HIS | 47643-2 | µmol/L |

| Homocitrulline | HOMOCIT | 53158-2 | µmol/L |
|-----------------|---------|---------|--------|
| Lysine | LYS | 47689-5 | µmol/L |
| Methionine | MET | 47700-0 | µmol/L |
| Methylhistidine | CH3HIS | 47539-2 | µmol/L |
| Phenylalanine | PHE | 29573-3 | µmol/L |
| Proline | PRO | 47732-3 | µmol/L |
| Serine | SER | 47742-2 | µmol/L |
| Succinylacetone | SUAC | 53231-7 | µmol/L |
| Threonine | THR | 47784-4 | µmol/L |
| Tryptophan | TRP | 53159-0 | µmol/L |
| Tyrosine | TYR | 35571-9 | µmol/L |
| Valine | VAL | 47799-2 | µmol/L |

MS/MS: Amino Acids Computed Sums and Ratios

| Analyte | Short Name | LOINC Code | Units |
|--|-------------------------------------|------------|----------------|
| Alanine + Beta Alanine + Sarcosine | ALA + BALA + SARC | 53150-9 | µmol/L |
| Alloisoleucine + Isoleucine + Leucine + Hydroxyproline | AILE + ILE + LEU + OHPRO | 53152-5 | µmol/L |
| Alloisoleucine + Isoleucine + Leucine + Hydroxyproline / Phenylalanine Ratio | [AILE + ILE + LEU + OHPRO] / PHE | 53153-3 | molar ratio |
| Alloisoleucine + Isoleucine + Leucine + Hydroxyproline /Alanine | [AILE + ILE + LEU + OHPRO] / ALA | 53154-1 | molar ratio |
| Arginine / Phenylalanine Ratio | ARG / PHE | 53398-4 | TBD |
| Argininosuccinate / Arginine Ratio | ASA / ARG | 53200-2 | molar ratio |
| Asparagine + Ornithine | ASN + ORN | 53155-8 | µmol/L |
| Asparagine + Ornithine / Phenylalanine Ratio | [ASN + ORN] / PHE | 53396-8 | molar ratio |
| Asparagine + Ornithine / Serine Ratio | [ASN + ORN] / SER | 53395-0 | molar ratio |

| SOMAN SEAC | CES-LEY |
|------------|----------|
| | |
| 、イ | |
| DELVELIN | <u> </u> |

| Citrulline / Phenylalanine Ratio | CIT / PHE | 53157-4 | molar ratio |
|---|---------------------------------------|---------|----------------|
| Citrulline / Tyrosine Ratio | CIT / TYR | 53399-2 | molar ratio |
| Methionine / Alloisoleucine + Isoleucine + Leucine + Hydroxyproline Ratio | MET / [AILE + ILE + LEU + OHPRO] | 53397-6 | molar ratio |
| Methionine / Phenylalanine Ratio | MET / PHE | 53156-6 | molar ratio |
| Oxoproline + Pipecolate | OXOPRO + PIPA | 53232-5 | µmol/L |
| Oxoproline + Pipecolate / Phenylalanine Ratio | [OXOPRO + PIPA] / PHE | 53394-3 | molar ratio |
| Phenylalanine / Tyrosine Ratio | PHE / TYR | 35572-7 | molar ratio |
| Proline / Phenylalanine Ratio | PRO / PHE | 53392-7 | TBD |
| Valine / Phenylalanine Ratio | VAL/PHE | 53151-7 | molar ratio |
| Valine + Alloisoleucine + Isoleucine + Leucine + Hydroxyproline + Valine / Phenylalanine + Tyrosine Ratio | [AILE + ILE + LEU + OHPRO + VAL] / | 53393-5 | molar ratio |

MS/MS: Acyl-Carnitine

| Analyte | Short Name | LOINC Code | Units |
|---------------------------------|------------|------------|--------|
| Decatrienoylcarnitine | C10:3 | 53208-5 | µmol/L |
| Dehydrosebacylcarnitine | C10:1DC | 53211-9 | µmol/L |
| Dehydrosuberylcarnitine | C8:1DC | 53209-3 | µmol/L |
| Dicarboxydodecanoylcarnitine | C12DC | 53214-3 | µmol/L |
| Dicarboxydodecenoylcarnitine | C12:1DC | 53213-5 | µmol/L |
| Dicarboxyoleylcarnitine | C18:1DC | 53219-2 | µmol/L |
| Dicarboxypalmitoleylcarnitine | C16:1DC | 53217-6 | µmol/L |
| Dicarboxypalmitoylcarnitine | C16DC | 53218-4 | µmol/L |
| Dicarboxystearoylcarnitine | C18DC | 53220-0 | µmol/L |
| Dicarboxytetradecanoylcarnitine | C14DC | 53216-8 | µmol/L |
| Dicarboxytetradecenoylcarnitine | C14:1DC | 53215-0 | µmol/L |

| Heptanoylcarnitine | C7 | 53204-4 | µmol/L |
|-----------------------|-------|---------|--------|
| Hexenoylcarnitine | C6:1 | 53203-6 | µmol/L |
| Nonanoylcarnitine | C9 | 53207-7 | µmol/L |
| Octenoylcarnitine | C8:1 | 53174-9 | µmol/L |
| Phenylacetylcarnitine | PHEC2 | 53205-1 | µmol/L |
| Salicylylcarnitine | SALC | 53206-9 | µmol/L |
| Sebacylcarnitine | C10DC | 53212-7 | µmol/L |
| Suberylcarnitine | C8DC | 53210-1 | µmol/L |

MS/MS: Fatty Acid Oxidase

| Analyte | Short Name | LOINC Code | Units |
|----------------------------|------------|------------|--------|
| Carnitine.free | C0 | 38481-8 | µmol/L |
| Decadienoylcarnitine | C10:2 | 53180-6 | µmol/L |
| Decanoylcarnitine | C10 | 45197-1 | µmol/L |
| Decenoylcarnitine | C10:1 | 45198-9 | µmol/L |
| Dodecanoylcarnitine | C12 | 45199-7 | µmol/L |
| Dodecenoylcarnitine | C12:1 | 45200-3 | µmol/L |
| Hexanoylcarnitine | C6 | 45211-0 | µmol/L |
| Hydroxybutyrylcarnitine | С4ОН | 50102-3 | µmol/L |
| Hydroxydecenoylcarnitine | C10:10H | 53182-2 | µmol/L |
| Hydroxydodecanoylcarnitine | С120Н | 53189-7 | µmol/L |
| Hydroxydodecenoylcarnitine | C12:10H | 53188-9 | µmol/L |
| Hydroxyhexanoylcarnitine | С6ОН | 53173-1 | µmol/L |
| Hydroxylinoleoylcarnitine | C18:20H | 50109-8 | µmol/L |

| Hydroxyoleylcarnitine | C18:10H | 50113-0 | µmol/L |
|---------------------------------|---------|---------|--------|
| Hydroxypalmitoleylcarnitine | C16:10H | 50121-3 | µmol/L |
| Hydroxypalmitoylcarnitine | C16OH | 50125-4 | µmol/L |
| Hydroxystearoylcarnitine | C18OH | 50132-0 | µmol/L |
| Hydroxytetradecadienylcarnitine | C14:20H | 53196-2 | µmol/L |
| Hydroxytetradecanoylcarnitine | C14OH | 50281-5 | µmol/L |
| Hydroxytetradecenoylcarnitine | C14:10H | 53197-0 | µmol/L |
| Linoleoylcarnitine | C18:2 | 45217-7 | µmol/L |
| Octanoylcarnitine | C8 | 53175-6 | µmol/L |
| Oleylcarnitine | C18:1 | 53202-8 | µmol/L |
| Palmitoleylcarnitine | C16:1 | 53198-8 | µmol/L |
| Palmitoylcarnitine | C16 | 53199-6 | µmol/L |
| Stearoylcarnitine | C18 | 53241-6 | µmol/L |
| Tetradecadienoylcarnitine | C14:2 | 53190-5 | µmol/L |
| Tetradecanoylcarnitine | C14 | 53192-1 | µmol/L |
| Tetradecenoylcarnitine | C14:1 | 53191-3 | µmol/L |

MS/MS: Fatty Acid Oxidase Computed Sums and Ratios

| Analyte | Short Name | LOINC Code | Units |
|---|---------------------------------------|------------|----------------|
| Carnitine.free / Palmitoylcarnitine+Stearoylcarnitine Ratio | C0 / [C16 + C18] | 53235-8 | molar ratio |
| Carnitine.free / Palmitoylcarnitine Ratio | C0 / C16 | 53233-3 | molar ratio |
| Carnitine.free / Stearoylcarnitine Ratio | C0 / C18 | 53234-1 | molar ratio |
| Carnitine.free + Acetylcarnitine + Propionylcarnitine + Palmitoylcarnitine + Oleylcarnitine + Stearoylcarnitine /Citrulline Ratio | [C0 + C2 + C3 + C16 + C18:1 + C18] | 53236-6 | molar ratio |
| Hydroxypalmitoylcarnitine / Palmitoylcarnitine Ratio | C16OH / C16 | 53201-0 | molar ratio |

| Octanoylcarnitine / Acetylcarnitine Ratio | C8 / C2 | 53176-4 | molar ratio |
|--|---------------|---------|----------------|
| Octanoylcarnitine / Decanoylcarnitine Ratio | C8 / C10 | 53177-2 | molar ratio |
| Stearoylcarnitine / Propionylcarnitine Ratio | C18 / C3 | 53400-8 | molar ratio |
| Tetradecenoylcarnitine / Palmitoylcarnitine Ratio | C14:1 / C16 | 53195-4 | molar ratio |
| Tetradecenoylcarnitine / Acetylcarnitine Ratio | C14:1 / C2 | 53193-9 | molar ratio |
| Tetradecenoylcarnitine / Dodecenoylcarnitine Ratio | C14:1 / C12:1 | 53194-7 | molar ratio |

MS/MS: Fatty Acid Oxidase-Organic Acids

| Analyte | Short Name | LOINC Code | Units |
|-----------------|------------|------------|--------|
| Acetylcarnitine | C2 | 50157-7 | µmol/L |

MS/MS: Fatty Acid Oxidase-Organic Acids

Computed Sums and Ratios

| Analyte | Short Name | LOINC Code | Units |
|--|------------------------|------------|----------------|
| Butyrylcarnitine + Isobutyrylcarnitine | C4 | 53166-5 | µmol/L |
| Butyrylcarnitine + Isobutyrylcarnitine / Acetylcarnitine Ratio | C4 / C2 | 53167-3 | molar ratio |
| Butyrylcarnitine + Isobutyrylcarnitine / Octanoylcarnitine Ratio | C4 / C8 | 53169-9 | molar ratio |
| Butyrylcarnitine + Isobutyrylcarnitine / Propionylcarnitine Ratio | C4 / C3 | 53168-1 | molar ratio |
| Glutarylcarnitine + Hydroxydecanoylcarnitine | C5DC + C10OH | 53183-0 | µmol/L |
| Glutarylcarnitine + Hydroxydecanoylcarnitine / Hydroxyisovalerylcarnitine Ratio | C5DC + C10OH / C5OH | 53184-8 | molar ratio |
| Glutarylcarnitine + Hydroxydecanoylcarnitine / Octanoylcarnitine Ratio | C5DC + C10OH / C8 | 53185-5 | molar ratio |
| Glutarylcarnitine + Hydroxydecanoylcarnitine / Palmitoylcarnitine Ratio | C5DC + C10OH / C16 | 53186-3 | molar ratio |
| Glutarylcarnitine + Hydroxydecanoylcarnitine /Butyrylcarnitine + Isobutyrylcarnitine Ratio | C5DC + C10OH / C4 | 53403-2 | molar ratio |
| Hydroxyoctanoylcarnitine + Malonylcarnitine | C8OH + C3DC | 53178-0 | µmol/L |
| Hydroxyoctanoylcarnitine + Malonylcarnitine / Butyrylcarnitine + Isobutyrylcarnitine Ratio | C8OH + C3DC / C4 | 53402-4 | molar ratio |
| Hydroxyoctanoylcarnitine + Malonylcarnitine / Decanoylcarnitine Ratio | C8OH + C3DC / C10 | 53179-8 | molar ratio |

A REAL PROPERTY OF THE PROPERT

MS/MS: Organic Acids

| Analyte | Short Name | LOINC Code | Units |
|----------------------------|------------|------------|--------|
| Formiminoglutamic acid | FIGLU | 53165-7 | µmol/L |
| Hydroxyisovalerylcarnitine | С5ОН | 50106-4 | µmol/L |
| Methylglutarylcarnitine | C6DC | 53187-1 | µmol/L |
| Methylmalonylcarnitine | C4DC | 45222-7 | µmol/L |
| Propenoylcarnitine | C3:1 | 53237-4 | µmol/L |
| Propionylcarnitine | C3 | 53160-8 | µmol/L |
| Tiglylcarnitine | C5:1 | 53170-7 | µmol/L |

MS/MS: Organic Acids Computed Sums and Ratios

| Analyte | Short Name | LOINC Code | Units |
|---|-------------|------------|----------------|
| Hydroxyisovalerylcarnitine / Carnitine.free Ratio | C5OH / C0 | 53171-5 | molar ratio |
| Hydroxyisovalerylcarnitine / Octanoylcarnitine Ratio | C50H / C8 | 53172-3 | molar ratio |
| Isovalerylcarnitine + Methylbutyrylcarnitine | C5 | 45216-9 | µmol/L |
| Isovalerylcarnitine + Methylbutyrylcarnitine / Acetylcarnitine Ratio | C5 / C2 | 53239-0 | molar ratio |
| Isovalerylcarnitine + Methylbutyrylcarnitine / Carnitine.free Ratio | C5 / C0 | 53238-2 | molar ratio |
| Isovalerylcarnitine + Methylbutyrylcarnitine / Octanoylcarnitine Ratio | C5 / C8 | 53401-6 | molar ratio |
| Isovalerylcarnitine + Methylbutyrylcarnitine / Propionylcarnitine Ratio | C5 / C3 | 53240-8 | molar ratio |
| Methylmalonylcarnitine / Hydroxyisovalerylcarnitine Ratio | C4DC / C5OH | 53181-4 | molar ratio |
| Propionylcarnitine / Acetylcarnitine Ratio | C3 / C2 | 53163-2 | molar ratio |
| Propionylcarnitine / Carnitine.free Ratio | C3 / C0 | 53162-4 | molar ratio |
| Propionylcarnitine / Methionine Ratio | C3 / MET | 53161-6 | molar ratio |
| Propionylcarnitine / Palmitoylcarnitine Ratio | C3 / C16 | 53164-0 | molar ratio |

A DAY AND A DAY

Non-MS/MS:

| Analyte | Short Name | LOINC Code | Units |
|-------------|------------|------------|-------|
| Biotinidase | BIO | TBD | TBD |

Non-MS/MS: Cystic Fibrosis

| Analyte | Short Name | LOINC Code | Units |
|---------------------------------|------------|------------|------------------|
| CFTR mutation variant panel | TBD | TBD | Specific alleles |
| DNA sequencing of the CFTR gene | TBD | TBD | TBD |
| Immunoreactive trypsinogen | IRT | TBD | ng/mL |
| Sweat chloride | TBD | TBD | TBD |

Non-MS/MS: Endocrine Disorders

| Analyte | Short Name | LOINC Code | Units |
|-------------------------|------------|------------|-------|
| 11-deoxycortisol | TBD | 53338-0 | ng/mL |
| 17-hydroxy progesterone | 170HP | 38473-5 | ng/mL |
| 21-deoxycortisol | TBD | 53341-4 | ng/mL |
| Androstenedione | TBD | 53343-0 | ng/mL |
| Cortisol | TBD | 53345-5 | ng/mL |
| Deoxycorticosterone | твр | 53347-1 | ng/mL |
| Τ4 | T4 | 53349-7 | ng/dL |
| TSH | TSH | 29575-8 | mIU/L |

Non-MS/MS: Endocrine Disorders Computed Sums and Ratios

| Analyte | Short Name | LOINC Code | Units |
|----------------------------------|------------|------------|-------|
| (17OHP+Androstenedione)/cortisol | TBD | 53336-4 | TBD |



Non-MS/MS: Galactosemia

| Analyte | Short Name | LOINC Code | Units |
|---------------|------------|------------|-------|
| Enzyme NADPH5 | TBD | TBD | mg/dL |
| Galactose | TBD | TBD | mg/dL |

Non-MS/MS: Hemoglobin Disorders

| Analyte | Short Name | LOINC Code | Units |
|--|-----------------|------------|----------|
| Electrophoresis (Cellulose Acetate and Citrate Agar) | Electrophoresis | TBD | Disorder |
| High Performance Liquid Chromatography | HPLC | TBD | Disorder |
| Isoelectric Focusing | IEF | TBD | Disorder |
| Percent Hemoglobin A | %HgB A | TBD | % |
| Percent Hemoglobin B | %HgB B | TBD | % |
| Percent Hemoglobin Barts | %HgB Barts | TBD | % |
| Percent Hemoglobin C | %HgB C | TBD | % |
| Percent Hemoglobin D | %HgB D | TBD | % |
| Percent Hemoglobin E | %HgB E | TBD | % |
| Percent Hemoglobin F | %HgB F | TBD | % |
| Percent Hemoglobin OARAB | %HgB OARAB | TBD | % |
| Percent Hemoglobin S | %HgB S | TBD | % |

Non-MS/MS: Infectious Diseases

| Analyte | Short Name | LOINC Code | Units |
|---|------------|------------|---------------|
| Human immunodeficiency virus IgG antibodies | TBD | TBD | Pos or Neg |
| Toxoplasmosis IgG | TBD | TBD | Pos or Neg |
| Toxoplasmosis IgM antibodies | TBD | TBD | Pos or Neg |

MS/MS Analytes

Ordered By Molecular Weight.

Analyte Categories : AA - Amino Acids AC - Acyl-Carnitine FAO - Fatty Acid Oxidase FAO-OA - Fatty Acid Oxidase - Organic Acids OA - Organic Acids

| Analyte | Category | Short Name | LOINC Code | Units |
|--|----------|---------------------------------------|------------|----------------|
| Glycine | AA | GLY | 47633-3 | µmol/L |
| Alanine + Beta Alanine + Sarcosine | AA | ALA + BALA + SARC | 53150-9 | µmol/L |
| Succinylacetone | AA | SUAC | 53231-7 | µmol/L |
| Serine | AA | SER | 47742-2 | µmol/L |
| Proline | AA | PRO | 47732-3 | µmol/L |
| Proline / Phenylalanine Ratio | AA | PRO / PHE | 53392-7 | TBD |
| Valine | AA | VAL | 47799-2 | µmol/L |
| Valine / Phenylalanine Ratio | AA | VAL/PHE | 53151-7 | molar ratio |
| Valine + Alloisoleucine + Isoleucine + Leucine + Hydroxyproline + Valine / Phenylalanine + Tyrosine Ratio | AA | [AILE + ILE + LEU + OHPRO + VAL] / | 53393-5 | molar ratio |
| Threonine | АА | THR | 47784-4 | µmol/L |
| Oxoproline + Pipecolate | AA | OXOPRO + PIPA | 53232-5 | µmol/L |
| Oxoproline + Pipecolate / Phenylalanine Ratio | AA | [OXOPRO + PIPA] / PHE | 53394-3 | molar ratio |
| Alloisoleucine + Isoleucine + Leucine + Hydroxyproline | AA | AILE + ILE + LEU + OHPRO | 53152-5 | µmol/L |
| Alloisoleucine + Isoleucine + Leucine + Hydroxyproline / Phenylalanine Ratio | AA | [AILE + ILE + LEU + OHPRO] / PHE | 53153-3 | molar ratio |
| Alloisoleucine + Isoleucine + Leucine + Hydroxyproline /Alanine | AA | [AILE + ILE + LEU + OHPRO] / ALA | 53154-1 | molar ratio |
| Asparagine + Ornithine | AA | ASN + ORN | 53155-8 | µmol/L |
| Asparagine + Ornithine / Serine Ratio | AA | [ASN + ORN] / SER | 53395-0 | molar ratio |
| Asparagine + Ornithine / Phenylalanine Ratio | AA | [ASN + ORN] / PHE | 53396-8 | molar ratio |
| Lysine | AA | LYS | 47689-5 | µmol/L |



| Analyte | Category | Short Name | LOINC Code | Units |
|---|----------|---------------------------------------|------------|----------------|
| Methionine | AA | MET | 47700-0 | µmol/L |
| Methionine / Phenylalanine Ratio | AA | MET / PHE | 53156-6 | molar ratio |
| Methionine / Alloisoleucine + Isoleucine + Leucine + Hydroxyproline Ratio | AA | MET / [AILE + ILE + LEU + OHPRO] | 53397-6 | molar ratio |
| Histidine | AA | HIS | 47643-2 | µmol/L |
| Carnitine.free | FAO | C0 | 38481-8 | µmol/L |
| Carnitine.free / Palmitoylcarnitine Ratio | FAO | C0 / C16 | 53233-3 | molar ratio |
| Carnitine.free / Stearoylcarnitine Ratio | FAO | C0 / C18 | 53234-1 | molar ratio |
| Carnitine.free / Palmitoylcarnitine+Stearoylcarnitine Ratio | FAO | C0 / [C16 + C18] | 53235-8 | molar ratio |
| Carnitine.free + Acetylcarnitine + Propionylcarnitine + Palmitoylcarnitine + Oleylcarnitine + Stearoylcarnitine /Citrulline Ratio | FAO | [C0 + C2 + C3 + C16 + C18:1 + C18] | 53236-6 | molar ratio |
| Phenylalanine | AA | PHE | 29573-3 | µmol/L |
| Phenylalanine / Tyrosine Ratio | AA | PHE / TYR | 35572-7 | molar ratio |
| Arginine | AA | ARG | 47562-4 | µmol/L |
| Arginine / Phenylalanine Ratio | AA | ARG / PHE | 53398-4 | TBD |
| Citrulline | AA | CIT | 42892-0 | µmol/L |
| Citrulline / Phenylalanine Ratio | AA | CIT / PHE | 53157-4 | molar ratio |
| Citrulline / Tyrosine Ratio | AA | CIT / TYR | 53399-2 | molar ratio |
| Tyrosine | AA | TYR | 35571-9 | µmol/L |
| Aspartate | AA | ASP | 47573-1 | µmol/L |
| Homocitrulline | AA | HOMOCIT | 53158-2 | µmol/L |
| Acetylcarnitine | FAO-OA | C2 | 50157-7 | µmol/L |
| Glutamate | AA | GLU | 47623-4 | µmol/L |
| Tryptophan | AA | TRP | 53159-0 | µmol/L |
| Propenoylcarnitine | OA | C3:1 | 53237-4 | µmol/L |



| Analyte | Category | Short Name | LOINC Code | Units |
|---|----------|------------|------------|----------------|
| Propionylcarnitine | OA | C3 | 53160-8 | µmol/L |
| Propionylcarnitine / Methionine Ratio | OA | C3 / MET | 53161-6 | molar ratio |
| Propionylcarnitine / Carnitine.free Ratio | OA | C3 / C0 | 53162-4 | molar ratio |
| Propionylcarnitine / Acetylcarnitine Ratio | OA | C3 / C2 | 53163-2 | molar ratio |
| Propionylcarnitine / Palmitoylcarnitine Ratio | OA | C3 / C16 | 53164-0 | molar ratio |
| Formiminoglutamic acid | OA | FIGLU | 53165-7 | µmol/L |
| Butyrylcarnitine + Isobutyrylcarnitine | FAO-OA | C4 | 53166-5 | µmol/L |
| Butyrylcarnitine + Isobutyrylcarnitine / Acetylcarnitine Ratio | FAO-OA | C4 / C2 | 53167-3 | molar ratio |
| Butyrylcarnitine + Isobutyrylcarnitine / Propionylcarnitine Ratio | FAO-OA | C4 / C3 | 53168-1 | molar ratio |
| Butyrylcarnitine + Isobutyrylcarnitine / Octanoylcarnitine Ratio | FAO-OA | C4 / C8 | 53169-9 | molar ratio |
| Tiglylcarnitine | OA | C5:1 | 53170-7 | µmol/L |
| Isovalerylcarnitine + Methylbutyrylcarnitine | OA | C5 | 45216-9 | µmol/L |
| Isovalerylcarnitine + Methylbutyrylcarnitine / Carnitine.free Ratio | OA | C5 / C0 | 53238-2 | molar ratio |
| Isovalerylcarnitine + Methylbutyrylcarnitine / Acetylcarnitine Ratio | OA | C5 / C2 | 53239-0 | molar ratio |
| Isovalerylcarnitine + Methylbutyrylcarnitine / Propionylcarnitine Ratio | OA | C5 / C3 | 53240-8 | molar ratio |
| Isovalerylcarnitine + Methylbutyrylcarnitine / Octanoylcarnitine Ratio | OA | C5 / C8 | 53401-6 | molar ratio |
| Hydroxybutyrylcarnitine | FAO | С4ОН | 50102-3 | µmol/L |
| Hexanoylcarnitine | FAO | C6 | 45211-0 | µmol/L |
| Hydroxyisovalerylcarnitine | OA | С5ОН | 50106-4 | µmol/L |
| Hydroxyisovalerylcarnitine / Carnitine.free Ratio | OA | С5ОН / С0 | 53171-5 | molar ratio |
| Hydroxyisovalerylcarnitine / Octanoylcarnitine Ratio | OA | C50H / C8 | 53172-3 | molar ratio |
| Hydroxyhexanoylcarnitine | FAO | С6ОН | 53173-1 | µmol/L |
| Octenoylcarnitine | AC | C8:1 | 53174-9 | µmol/L |

| E-NOAAN | A SERV | ICEs. | Les a |
|----------|--------|-------|-------|
| Heren | | | 9 |
| - | へ | {{ | 2 |
| NOTELS . | iaa i | C | |

| Analyte | Category | Short Name | LOINC Code | Units |
|--|----------|------------------------|------------|----------------|
| Octanoylcarnitine | FAO | C8 | 53175-6 | µmol/L |
| Octanoylcarnitine / Acetylcarnitine Ratio | FAO | C8 / C2 | 53176-4 | molar ratio |
| Octanoylcarnitine / Decanoylcarnitine Ratio | FAO | C8 / C10 | 53177-2 | molar ratio |
| Hydroxyoctanoylcarnitine + Malonylcarnitine | FAO-OA | C8OH + C3DC | 53178-0 | µmol/L |
| Hydroxyoctanoylcarnitine + Malonylcarnitine / Butyrylcarnitine + Isobutyrylcarnitine Ratio | FAO-OA | C8OH + C3DC / C4 | 53402-4 | molar ratio |
| Hydroxyoctanoylcarnitine + Malonylcarnitine / Decanoylcarnitine Ratio | FAO-OA | C8OH + C3DC / C10 | 53179-8 | molar ratio |
| Decadienoylcarnitine | FAO | C10:2 | 53180-6 | µmol/L |
| Decenoylcarnitine | FAO | C10:1 | 45198-9 | µmol/L |
| Decanoylcarnitine | FAO | C10 | 45197-1 | µmol/L |
| Methylmalonylcarnitine | OA | C4DC | 45222-7 | µmol/L |
| Methylmalonylcarnitine / Hydroxyisovalerylcarnitine Ratio | OA | C4DC / C5OH | 53181-4 | molar ratio |
| Hydroxydecenoylcarnitine | FAO | C10:10H | 53182-2 | µmol/L |
| Glutarylcarnitine + Hydroxydecanoylcarnitine | FAO-OA | C5DC + C10OH | 53183-0 | µmol/L |
| Glutarylcarnitine + Hydroxydecanoylcarnitine /Butyrylcarnitine + Isobutyrylcarnitine Ratio | FAO-OA | C5DC + C10OH / C4 | 53403-2 | molar ratio |
| Glutarylcarnitine + Hydroxydecanoylcarnitine / Hydroxyisovalerylcarnitine Ratio | FAO-OA | C5DC + C10OH / C5OH | 53184-8 | molar ratio |
| Glutarylcarnitine + Hydroxydecanoylcarnitine / Octanoylcarnitine Ratio | FAO-OA | C5DC + C10OH / C8 | 53185-5 | molar ratio |
| Glutarylcarnitine + Hydroxydecanoylcarnitine / Palmitoylcarnitine Ratio | FAO-OA | C5DC + C10OH / C16 | 53186-3 | molar ratio |
| Dodecenoylcarnitine | FAO | C12:1 | 45200-3 | µmol/L |
| Dodecanoylcarnitine | FAO | C12 | 45199-7 | µmol/L |
| Methylglutarylcarnitine | OA | C6DC | 53187-1 | µmol/L |
| Hydroxydodecenoylcarnitine | FAO | C12:10H | 53188-9 | µmol/L |
| Hydroxydodecanoylcarnitine | FAO | С12ОН | 53189-7 | µmol/L |
| Tetradecadienoylcarnitine | FAO | C14:2 | 53190-5 | µmol/L |



| Analyte | Category | Short Name | LOINC Code | Units |
|--|----------|---------------|------------|----------------|
| Tetradecenoylcarnitine | FAO | C14:1 | 53191-3 | µmol/L |
| Tetradecanoylcarnitine | FAO | C14 | 53192-1 | µmol/L |
| Tetradecenoylcarnitine / Acetylcarnitine Ratio | FAO | C14:1 / C2 | 53193-9 | molar ratio |
| Tetradecenoylcarnitine / Dodecenoylcarnitine Ratio | FAO | C14:1 / C12:1 | 53194-7 | molar ratio |
| Tetradecenoylcarnitine / Palmitoylcarnitine Ratio | FAO | C14:1 / C16 | 53195-4 | molar ratio |
| Hydroxytetradecadienylcarnitine | FAO | C14:2OH | 53196-2 | µmol/L |
| Hydroxytetradecenoylcarnitine | FAO | C14:10H | 53197-0 | µmol/L |
| Hydroxytetradecanoylcarnitine | FAO | C14OH | 50281-5 | µmol/L |
| Palmitoleylcarnitine | FAO | C16:1 | 53198-8 | µmol/L |
| Palmitoylcarnitine | FAO | C16 | 53199-6 | µmol/L |
| Argininosuccinate | AA | ASA | 53062-6 | µmol/L |
| Argininosuccinate / Arginine Ratio | AA | ASA / ARG | 53200-2 | molar ratio |
| Hydroxypalmitoleylcarnitine | FAO | C16:1OH | 50121-3 | µmol/L |
| Hydroxypalmitoylcarnitine | FAO | C16OH | 50125-4 | µmol/L |
| Hydroxypalmitoylcarnitine / Palmitoylcarnitine Ratio | FAO | C16OH / C16 | 53201-0 | molar ratio |
| Linoleoylcarnitine | FAO | C18:2 | 45217-7 | µmol/L |
| Oleylcarnitine | FAO | C18:1 | 53202-8 | µmol/L |
| Stearoylcarnitine | FAO | C18 | 53241-6 | µmol/L |
| Stearoylcarnitine / Propionylcarnitine Ratio | FAO | C18 / C3 | 53400-8 | molar ratio |
| Hydroxylinoleoylcarnitine | FAO | C18:2OH | 50109-8 | µmol/L |
| Hydroxyoleylcarnitine | FAO | C18:10H | 50113-0 | µmol/L |
| Hydroxystearoylcarnitine | FAO | С18ОН | 50132-0 | µmol/L |
| Methylhistidine | AA | CH3HIS | 47539-2 | µmol/L |



| Analyte | Category | Short Name | LOINC Code | Units |
|---------------------------------|----------|------------|------------|--------|
| Hexenoylcarnitine | AC | C6:1 | 53203-6 | µmol/L |
| Heptanoylcarnitine | AC | C7 | 53204-4 | µmol/L |
| Phenylacetylcarnitine | AC | PHEC2 | 53205-1 | µmol/L |
| Salicylylcarnitine | AC | SALC | 53206-9 | µmol/L |
| Nonanoylcarnitine | AC | C9 | 53207-7 | µmol/L |
| Decatrienoylcarnitine | AC | C10:3 | 53208-5 | µmol/L |
| Dehydrosuberylcarnitine | AC | C8:1DC | 53209-3 | µmol/L |
| Suberylcarnitine | AC | C8DC | 53210-1 | µmol/L |
| Dehydrosebacylcarnitine | AC | C10:1DC | 53211-9 | µmol/L |
| Sebacylcarnitine | AC | C10DC | 53212-7 | µmol/L |
| Dicarboxydodecenoylcarnitine | AC | C12:1DC | 53213-5 | µmol/L |
| Dicarboxydodecanoylcarnitine | AC | C12DC | 53214-3 | µmol/L |
| Dicarboxytetradecenoylcarnitine | AC | C14:1DC | 53215-0 | µmol/L |
| Dicarboxytetradecanoylcarnitine | AC | C14DC | 53216-8 | µmol/L |
| Dicarboxypalmitoleylcarnitine | AC | C16:1DC | 53217-6 | µmol/L |
| Dicarboxypalmitoylcarnitine | AC | C16DC | 53218-4 | µmol/L |
| Dicarboxyoleylcarnitine | AC | C18:1DC | 53219-2 | µmol/L |
| Dicarboxystearoylcarnitine | AC | C18DC | 53220-0 | µmol/L |

MS/MS Analytes

Grouped by Computed Sum or Ratio. Ordered by Molecular Weight. Analyte Categories : AA - Amino Acids AC - Acyl-Carnitine FAO - Fatty Acid Oxidase FAO-OA - Fatty Acid Oxidase - Organic Acids OA - Organic Acids

| Analyte | Category | Short Name | LOINC Code | Units |
|-----------------|----------|------------|------------|--------|
| Glycine | AA | GLY | 47633-3 | µmol/L |
| Succinylacetone | AA | SUAC | 53231-7 | µmol/L |
| Serine | AA | SER | 47742-2 | µmol/L |
| Proline | AA | PRO | 47732-3 | µmol/L |
| Valine | AA | VAL | 47799-2 | µmol/L |
| Threonine | AA | THR | 47784-4 | µmol/L |
| Lysine | AA | LYS | 47689-5 | µmol/L |
| Methionine | AA | MET | 47700-0 | µmol/L |
| Histidine | AA | HIS | 47643-2 | µmol/L |
| Carnitine.free | FAO | CO | 38481-8 | µmol/L |
| Phenylalanine | AA | PHE | 29573-3 | µmol/L |
| Arginine | AA | ARG | 47562-4 | µmol/L |
| Citrulline | AA | СІТ | 42892-0 | µmol/L |
| Tyrosine | AA | TYR | 35571-9 | µmol/L |
| Aspartate | AA | ASP | 47573-1 | µmol/L |
| Homocitrulline | AA | HOMOCIT | 53158-2 | µmol/L |
| Acetylcarnitine | FAO-OA | C2 | 50157-7 | µmol/L |

L

| TypiopianAATEP33190µmoll.PropenoycamilneOAC31S1200µmoll.PropionycamilneOAC31S1800µmoll.Forminingulamic acidOAC31S1800µmoll.TglycamilneOAC31S1807µmoll.TglycamilneOAC31S1807µmoll.HydroxybutyrleamilneFAOC40HS1807µmoll.HydroxybutyrleamilneFAOC40HS1102µmoll.HydroxybutyrleamilneFAOC60HS1741µmoll.HydroxybutyrleamilneOAC60HS1741µmoll.OctensyleamilneFAOC60HS1742µmoll.OctensyleamilneFAOC101S1749µmoll.DecemoyleamilneFAOC101S1749µmoll.DecemoyleamilneFAOC101S1840µmoll.DecemoyleamilneFAOC101S1840µmoll.DecemoyleamilneFAOC101S1840µmoll.HydroxybocemoyleamilneFAOC101S1840µmoll.DecemoyleamilneFAOC101S1840µmoll.HydroxybocemoyleamilneFAOC121S1840µmoll.HydroxybocemoyleamilneFAOC121S1840µmoll.HydroxybocemoyleamilneFAOC121S1840µmoll.HydroxybocemoyleamilneFAOC121S1840µmoll.HydroxybocemoyleamilneFAOC121S1840µmoll. </th <th>Glutamate</th> <th>AA</th> <th>GLU</th> <th>47623-4</th> <th>µmol/L</th> | Glutamate | AA | GLU | 47623-4 | µmol/L |
|--|----------------------------|-----|---------|---------|--------|
| ProponylcamitinennnnnProgionylcamitineSilleSillegm/dlFormininogulamic acidOAFicLUSilleS-7µm/dlTglylcamitineOASilleXSilleXgm/dlHydroxybuylylcamitineFAOC4 OHSilleXgm/dlHydroxyboxaleryicamitineFAOC6 OHSilleXgm/dlHydroxyboxaleryicamitineOASilleXSilleXgm/dlHydroxyboxaleryicamitineFAOC6 OHSilleXgm/dlDictemoylcamitineFAOC8 OHSilleXgm/dlDictemoylcamitineFAOC8 OHSilleXgm/dlDecenoylcamitineFAOC101SilleXgm/dlDecenoylcamitineFAOC101SilleXgm/dlDecenoylcamitineFAOC101SilleXgm/dlDecenoylcamitineFAOC101SilleXgm/dlHydroxydoecenoylcamitineFAOC101SilleXgm/dlDictemoylcamitineFAOC101SilleXgm/dlHydroxydoecenoylcamitineFAOC121SilleXgm/dlHydroxydoecenoylcamitineFAOSilleXSilleXgm/dlHydroxydoecenoylcamitineFAOC121SilleXgm/dlHydroxydoecenoylcamitineFAOC121SilleXgm/dlHydroxydoecenoylcamitineFAOC120HSilleXgm/dlHydroxydoecenoylcamitineFAOC120HSilleXgm/dlHydrox | Tryptophan | AA | TRP | 53159-0 | µmol/L |
| Image: constraint of the state of the sta | Propenoylcarnitine | OA | C3:1 | 53237-4 | µmol/L |
| Image: constraint of the state of the sta | Propionylcarnitine | OA | C3 | 53160-8 | µmol/L |
| Image: A constraint of the state of the s | Formiminoglutamic acid | OA | FIGLU | 53165-7 | µmol/L |
| Hextbody Hextbody Lambdy HydroxylsovellerylcamitineFAOC645211.0µmol/LHydroxylsovellerylcamitineOAC5OH50108-4µmol/LHydroxylsovellerylcamitineFAOC6OH53173-1µmol/LOctanoylcamitineFAOC8.1S3173-6µmol/LOctanoylcamitineFAOC8S3175-6µmol/LDecedienoylcamitineFAOC10.2S3180-6µmol/LDecenoylcamitineFAOC10.145198-9µmol/LDecenoylcamitineFAOC10.145192-1µmol/LDecenoylcamitineFAOC10.145192-1µmol/LDecenoylcamitineFAOC10.145192-1µmol/LDecenoylcamitineFAOC10.145192-1µmol/LDedecenoylcamitineFAOC10.153182-2µmol/LDodecenoylcamitineFAOC12.14520-3µmol/LDodecenoylcamitineFAOC12.145199-1µmol/LHydroxydodecenoylcamitineFAOC12.10HS3187-1µmol/LHydroxydodecenoylcamitineFAOC12.0HS3189-1µmol/LHydroxydodecenoylcamitineFAOC12.0HS3189-1µmol/LHydroxydodecenoylcamitineFAOC12.0HS3189-1µmol/LHydroxydodecenoylcamitineFAOC12.0HS3189-1µmol/LHydroxydodecenoylcamitineFAOC14.2S3180-5µmol/LHydroxydodecenoylcamitineFAOC14.2S3180-5µmol/L <td>TiglyIcarnitine</td> <td>OA</td> <td>C5:1</td> <td>53170-7</td> <td>µmol/L</td> | TiglyIcarnitine | OA | C5:1 | 53170-7 | µmol/L |
| HydroxylsovalerylcarnitineOACSOH50106-4µmol/LHydroxylsovalerylcarnitineFAOC6OH53173-1µmol/LOctenoylcarnitineFAOC6OH53173-1µmol/LOctenoylcarnitineFAOC8:153174-9µmol/LDecadienoylcarnitineFAOC10:253180-6µmol/LDecanoylcarnitineFAOC10:253180-6µmol/LDecanoylcarnitineFAOC10:145198-9µmol/LDecanoylcarnitineFAOC10:145197-1µmol/LDecanoylcarnitineFAOC10:10H53182-2µmol/LMethylmalonylcarnitineOAC4DC4522-7µmol/LDodecenoylcarnitineFAOC10:10H53182-2µmol/LDodecenoylcarnitineFAOC12:10H5318-1µmol/LHydroxydodecenoylcarnitineOAC6DC5318-1µmol/LHydroxydodecenoylcarnitineFAOC12:10H5318-2µmol/LHydroxydodecenoylcarnitineFAOC12:10H5318-1µmol/LHydroxydodecenoylcarnitineFAOC12:10H5318-1µmol/LHydroxydodecenoylcarnitineFAOC12:10H5318-1µmol/LHydroxydodecenoylcarnitineFAOC12:10H5318-1µmol/LHydroxydodecenoylcarnitineFAOC12:10H5318-1µmol/LHydroxydodecenoylcarnitineFAOC12:10H5318-1µmol/LHydroxydodecenoylcarnitineFAOC12:10H5318-1µmol/L <td>Hydroxybutyrylcarnitine</td> <td>FAO</td> <td>С4ОН</td> <td>50102-3</td> <td>µmol/L</td> | Hydroxybutyrylcarnitine | FAO | С4ОН | 50102-3 | µmol/L |
| Image: Constraint of the state of | Hexanoylcarnitine | FAO | C6 | 45211-0 | µmol/L |
| Decensive and the set of the | Hydroxyisovalerylcarnitine | OA | С5ОН | 50106-4 | µmol/L |
| ActionFAOCallS3175-6µmol/LDecadienoylcarnitineFAOC10:2S3180-6µmol/LDecenoylcarnitineFAOC10:145198-9µmol/LDecanoylcarnitineFAOC1045197-1µmol/LDecanoylcarnitineFAOC1045197-1µmol/LMethylmalonylcarnitineOAC4DC4522-7µmol/LDodecenoylcarnitineFAOC10:10H53182-2µmol/LDodecenoylcarnitineFAOC12:14520-3µmol/LDodecenoylcarnitineFAOC12:14520-3µmol/LMethylgultarylcarnitineOAC6DCS3187-1µmol/LHydroxydodecenoylcarnitineFAOC12:10HS3189-9µmol/LHydroxydodecenoylcarnitineFAOC12:0HS3189-7µmol/LHydroxydodecenoylcarnitineFAOC12:0HS3189-7µmol/LHydroxydodecenoylcarnitineFAOC12:0HS3189-7µmol/LHydroxydodecenoylcarnitineFAOC12:0HS3189-7µmol/LHydroxydodecenoylcarnitineFAOC12:0HS3189-7µmol/LHydroxydodecenoylcarnitineFAOC12:0HS3189-7µmol/LHydroxydodecenoylcarnitineFAOC12:0HS3189-7µmol/LHydroxydodecenoylcarnitineFAOC14:2S3190-5µmol/LHydroxydodecenoylcarnitineFAOFAOC14:2S3190-5µmol/LHydroxydodecenoylcarnitineFAOFAOFAOFAO< | Hydroxyhexanoylcarnitine | FAO | С6ОН | 53173-1 | µmol/L |
| Image: A constraint of the state | Octenoylcarnitine | AC | C8:1 | 53174-9 | µmol/L |
| Image: Constraint of the state of | Octanoylcarnitine | FAO | C8 | 53175-6 | µmol/L |
| Image: relation of the state of t | Decadienoylcarnitine | FAO | C10:2 | 53180-6 | µmol/L |
| Image: Methylmalonylcarnitine Im | Decenoylcarnitine | FAO | C10:1 | 45198-9 | µmol/L |
| HydroxydecenoylcarnitineFAOC10:1OH53182-2µmol/LDodecenoylcarnitineFAOC12:145200-3µmol/LDodecanoylcarnitineFAOC1245199-7µmol/LMethylglutarylcarnitineOAC6DC53187-1µmol/LHydroxydodecenoylcarnitineFAOC12:1OH53188-9µmol/LHydroxydodecenoylcarnitineFAOC12:1OH53189-7µmol/LHydroxydodecenoylcarnitineFAOC12:0H53189-7µmol/LHydroxydodecanoylcarnitineFAOC12:0H53189-7µmol/LTetradecadienoylcarnitineFAOC14:253190-5µmol/L | Decanoylcarnitine | FAO | C10 | 45197-1 | µmol/L |
| DodecenoylcarnitineFAOC12:145200-3µmol/LDodecanoylcarnitineFAOC1245199-7µmol/LMethylglutarylcarnitineOAC6DC53187-1µmol/LHydroxydodecenoylcarnitineFAOC12:10H53188-9µmol/LHydroxydodecanoylcarnitineFAOC12OH53189-7µmol/LTetradecadienoylcarnitineFAOC14:253190-5µmol/L | Methylmalonylcarnitine | OA | C4DC | 45222-7 | µmol/L |
| DodecanoylcarnitineFAOC1245199-7μmol/LMethylglutarylcarnitineOAC6DC53187-1μmol/LHydroxydodecenoylcarnitineFAOC12:10H53188-9μmol/LHydroxydodecanoylcarnitineFAOC12OH53189-7μmol/LTetradecadienoylcarnitineFAOC14:253190-5μmol/L | Hydroxydecenoylcarnitine | FAO | C10:10H | 53182-2 | µmol/L |
| MethylglutarylcarnitineOAC6DC53187-1µmol/LHydroxydodecenoylcarnitineFAOC12:10H53188-9µmol/LHydroxydodecanoylcarnitineFAOC12OH53189-7µmol/LTetradecadienoylcarnitineFAOC14:253190-5µmol/L | Dodecenoylcarnitine | FAO | C12:1 | 45200-3 | µmol/L |
| HydroxydodecenoylcarnitineFAOC12:10H53188-9µmol/LHydroxydodecanoylcarnitineFAOC120H53189-7µmol/LTetradecadienoylcarnitineFAOC14:253190-5µmol/L | Dodecanoylcarnitine | FAO | C12 | 45199-7 | µmol/L |
| Hydroxydodecanoylcarnitine FAO C12OH 53189-7 µmol/L Tetradecadienoylcarnitine FAO C14:2 53190-5 µmol/L | Methylglutarylcarnitine | OA | C6DC | 53187-1 | µmol/L |
| Tetradecadienoylcarnitine FAO C14:2 53190-5 μmol/L | Hydroxydodecenoylcarnitine | FAO | C12:10H | 53188-9 | µmol/L |
| | Hydroxydodecanoylcarnitine | FAO | С12ОН | 53189-7 | µmol/L |
| Tetradecenoylcarnitine FAO C14:1 53191-3 µmol/L | Tetradecadienoylcarnitine | FAO | C14:2 | 53190-5 | µmol/L |
| | Tetradecenoylcarnitine | FAO | C14:1 | 53191-3 | µmol/L |

J.C.

| Tetradecanoylcarnitine | FAO | C14 | 53192-1 | µmol/L |
|---------------------------------|-----|---------|---------|--------|
| Hydroxytetradecadienylcarnitine | FAO | C14:2OH | 53196-2 | µmol/L |
| Hydroxytetradecenoylcarnitine | FAO | C14:10H | 53197-0 | µmol/L |
| Hydroxytetradecanoylcarnitine | FAO | С14ОН | 50281-5 | µmol/L |
| Palmitoleylcarnitine | FAO | C16:1 | 53198-8 | µmol/L |
| Palmitoylcarnitine | FAO | C16 | 53199-6 | µmol/L |
| Argininosuccinate | AA | ASA | 53062-6 | µmol/L |
| Hydroxypalmitoleylcarnitine | FAO | C16:10H | 50121-3 | µmol/L |
| Hydroxypalmitoylcarnitine | FAO | C16OH | 50125-4 | µmol/L |
| Linoleoylcarnitine | FAO | C18:2 | 45217-7 | µmol/L |
| Oleylcarnitine | FAO | C18:1 | 53202-8 | µmol/L |
| Stearoylcarnitine | FAO | C18 | 53241-6 | µmol/L |
| Hydroxylinoleoylcarnitine | FAO | C18:2OH | 50109-8 | µmol/L |
| Hydroxyoleylcarnitine | FAO | C18:10H | 50113-0 | µmol/L |
| Hydroxystearoylcarnitine | FAO | C18OH | 50132-0 | µmol/L |
| Methylhistidine | AA | CH3HIS | 47539-2 | µmol/L |
| Hexenoylcarnitine | AC | C6:1 | 53203-6 | µmol/L |
| Heptanoylcarnitine | AC | C7 | 53204-4 | µmol/L |
| Phenylacetylcarnitine | AC | PHEC2 | 53205-1 | µmol/L |
| Salicylylcarnitine | AC | SALC | 53206-9 | µmol/L |
| Nonanoylcarnitine | AC | C9 | 53207-7 | µmol/L |
| Decatrienoylcarnitine | AC | C10:3 | 53208-5 | µmol/L |
| Dehydrosuberylcarnitine | AC | C8:1DC | 53209-3 | µmol/L |
| Suberylcarnitine | AC | C8DC | 53210-1 | µmol/L |



| Dehydrosebacylcarnitine | AC | C10:1DC | 53211-9 | µmol/L |
|---------------------------------|----|---------|---------|--------|
| Sebacylcarnitine | AC | C10DC | 53212-7 | µmol/L |
| Dicarboxydodecenoylcarnitine | AC | C12:1DC | 53213-5 | µmol/L |
| Dicarboxydodecanoylcarnitine | AC | C12DC | 53214-3 | µmol/L |
| Dicarboxytetradecenoylcarnitine | AC | C14:1DC | 53215-0 | µmol/L |
| Dicarboxytetradecanoylcarnitine | AC | C14DC | 53216-8 | µmol/L |
| Dicarboxypalmitoleylcarnitine | AC | C16:1DC | 53217-6 | µmol/L |
| Dicarboxypalmitoylcarnitine | AC | C16DC | 53218-4 | µmol/L |
| Dicarboxyoleylcarnitine | AC | C18:1DC | 53219-2 | µmol/L |
| Dicarboxystearoylcarnitine | AC | C18DC | 53220-0 | µmol/L |

Computed Sums and Ratios

| Analyte | Category | Short Name | LOINC Code | Units |
|--|----------|---------------------------------------|------------|----------------|
| Alanine + Beta Alanine + Sarcosine | AA | ALA + BALA + SARC | 53150-9 | µmol/L |
| Proline / Phenylalanine Ratio | AA | PRO / PHE | 53392-7 | TBD |
| Valine / Phenylalanine Ratio | AA | VAL/PHE | 53151-7 | molar ratio |
| Valine + Alloisoleucine + Isoleucine + Leucine + Hydroxyproline + Valine / Phenylalanine + Tyrosine Ratio | AA | [AILE + ILE + LEU + OHPRO + VAL] / | 53393-5 | molar ratio |
| Oxoproline + Pipecolate | AA | OXOPRO + PIPA | 53232-5 | µmol/L |
| Oxoproline + Pipecolate / Phenylalanine Ratio | AA | [OXOPRO + PIPA] / PHE | 53394-3 | molar ratio |
| Alloisoleucine + Isoleucine + Leucine + Hydroxyproline | AA | AILE + ILE + LEU + OHPRO | 53152-5 | µmol/L |
| Alloisoleucine + Isoleucine + Leucine + Hydroxyproline / Phenylalanine Ratio | AA | [AILE + ILE + LEU + OHPRO] / PHE | 53153-3 | molar ratio |
| Alloisoleucine + Isoleucine + Leucine + Hydroxyproline /Alanine | AA | [AILE + ILE + LEU + OHPRO] / ALA | 53154-1 | molar ratio |
| Asparagine + Ornithine | AA | ASN + ORN | 53155-8 | µmol/L |
| Asparagine + Ornithine / Serine Ratio | AA | [ASN + ORN] / SER | 53395-0 | molar ratio |



| Asparagine + Ornithine / Phenylalanine Ratio | AA | [ASN + ORN] / PHE | 53396-8 | molar ratio |
|---|--------|---------------------------------------|---------|----------------|
| Methionine / Phenylalanine Ratio | AA | MET / PHE | 53156-6 | molar ratio |
| Methionine / Alloisoleucine + Isoleucine + Leucine + Hydroxyproline Ratio | AA | MET / [AILE + ILE + LEU + OHPRO] | 53397-6 | molar ratio |
| Carnitine.free / Palmitoylcarnitine Ratio | FAO | C0 / C16 | 53233-3 | molar ratio |
| Carnitine.free / Stearoylcarnitine Ratio | FAO | C0 / C18 | 53234-1 | molar ratio |
| Carnitine.free / Palmitoylcarnitine+Stearoylcarnitine Ratio | FAO | C0 / [C16 + C18] | 53235-8 | molar ratio |
| Carnitine.free + Acetylcarnitine + Propionylcarnitine + Palmitoylcarnitine + Oleylcarnitine + Stearoylcarnitine /Citrulline Ratio | FAO | [C0 + C2 + C3 + C16 + C18:1 + C18] | 53236-6 | molar ratio |
| Phenylalanine / Tyrosine Ratio | AA | PHE / TYR | 35572-7 | molar ratio |
| Arginine / Phenylalanine Ratio | AA | ARG / PHE | 53398-4 | TBD |
| Citrulline / Phenylalanine Ratio | AA | CIT / PHE | 53157-4 | molar ratio |
| Citrulline / Tyrosine Ratio | AA | CIT / TYR | 53399-2 | molar ratio |
| Propionylcarnitine / Methionine Ratio | OA | C3 / MET | 53161-6 | molar ratio |
| Propionylcarnitine / Carnitine.free Ratio | OA | C3 / C0 | 53162-4 | molar ratio |
| Propionylcarnitine / Acetylcarnitine Ratio | OA | C3 / C2 | 53163-2 | molar ratio |
| Propionylcarnitine / Palmitoylcarnitine Ratio | OA | C3 / C16 | 53164-0 | molar ratio |
| Butyrylcarnitine + Isobutyrylcarnitine | FAO-OA | C4 | 53166-5 | µmol/L |
| Butyrylcarnitine + Isobutyrylcarnitine / Acetylcarnitine Ratio | FAO-OA | C4 / C2 | 53167-3 | molar ratio |
| Butyrylcarnitine + Isobutyrylcarnitine / Propionylcarnitine Ratio | FAO-OA | C4 / C3 | 53168-1 | molar ratio |
| Butyrylcarnitine + Isobutyrylcarnitine / Octanoylcarnitine Ratio | FAO-OA | C4 / C8 | 53169-9 | molar ratio |
| Isovalerylcarnitine + Methylbutyrylcarnitine | OA | C5 | 45216-9 | µmol/L |
| Isovalerylcarnitine + Methylbutyrylcarnitine / Carnitine.free Ratio | OA | C5 / C0 | 53238-2 | molar ratio |
| Isovalerylcarnitine + Methylbutyrylcarnitine / Acetylcarnitine Ratio | OA | C5 / C2 | 53239-0 | molar ratio |
| Isovalerylcarnitine + Methylbutyrylcarnitine / Propionylcarnitine Ratio | OA | C5 / C3 | 53240-8 | molar ratio |
| Isovalerylcarnitine + Methylbutyrylcarnitine / Octanoylcarnitine Ratio | OA | C5 / C8 | 53401-6 | molar ratio |
| December 40, 2000 Office of the National Coordinates for LL | | | | 04 |



| Hydroxyisovalerylcarnitine / Carnitine.free Ratio | OA | C5OH / C0 | 53171-5 | molar ratio |
|---|--------|------------------------|---------|----------------|
| Hydroxyisovalerylcarnitine / Octanoylcarnitine Ratio | OA | C50H / C8 | 53172-3 | molar ratio |
| Octanoylcarnitine / Acetylcarnitine Ratio | FAO | C8 / C2 | 53176-4 | molar ratio |
| Octanoylcarnitine / Decanoylcarnitine Ratio | FAO | C8 / C10 | 53177-2 | molar ratio |
| Hydroxyoctanoylcarnitine + Malonylcarnitine | FAO-OA | C8OH + C3DC | 53178-0 | µmol/L |
| Hydroxyoctanoylcarnitine + Malonylcarnitine / Butyrylcarnitine + Isobutyrylcarnitine Ratio | FAO-OA | C8OH + C3DC / C4 | 53402-4 | molar ratio |
| Hydroxyoctanoylcarnitine + Malonylcarnitine / Decanoylcarnitine Ratio | FAO-OA | C8OH + C3DC / C10 | 53179-8 | molar ratio |
| Methylmalonylcarnitine / Hydroxyisovalerylcarnitine Ratio | OA | C4DC / C5OH | 53181-4 | molar ratio |
| Glutarylcarnitine + Hydroxydecanoylcarnitine | FAO-OA | C5DC + C10OH | 53183-0 | µmol/L |
| Glutarylcarnitine + Hydroxydecanoylcarnitine /Butyrylcarnitine + Isobutyrylcarnitine Ratio | FAO-OA | C5DC + C10OH / C4 | 53403-2 | molar ratio |
| Glutarylcarnitine + Hydroxydecanoylcarnitine / Hydroxyisovalerylcarnitine Ratio | FAO-OA | C5DC + C10OH / C5OH | 53184-8 | molar ratio |
| Glutarylcarnitine + Hydroxydecanoylcarnitine / Octanoylcarnitine Ratio | FAO-OA | C5DC + C10OH / C8 | 53185-5 | molar ratio |
| Glutarylcarnitine + Hydroxydecanoylcarnitine / Palmitoylcarnitine Ratio | FAO-OA | C5DC + C10OH / C16 | 53186-3 | molar ratio |
| Tetradecenoylcarnitine / Acetylcarnitine Ratio | FAO | C14:1 / C2 | 53193-9 | molar ratio |
| Tetradecenoylcarnitine / Dodecenoylcarnitine Ratio | FAO | C14:1 / C12:1 | 53194-7 | molar ratio |
| Tetradecenoylcarnitine / Palmitoylcarnitine Ratio | FAO | C14:1 / C16 | 53195-4 | molar ratio |
| Argininosuccinate / Arginine Ratio | AA | ASA / ARG | 53200-2 | molar ratio |
| Hydroxypalmitoylcarnitine / Palmitoylcarnitine Ratio | FAO | C16OH / C16 | 53201-0 | molar ratio |
| Stearoylcarnitine / Propionylcarnitine Ratio | FAO | C18 / C3 | 53400-8 | molar ratio |

P THE REAL PROPERTY OF THE PRO

MS/MS Condition to Analyte Mapping

The MS/MS Condition to Analyte Mapping report lists the analytes or laboratory measures that may be abnormal in the presence of a condition or disorder (listed in boldface). The less common abnormal findings for each condition are marked as optional. The mapping of abnormal analytes to specific conditions is not precise and this listing is intended to guide looking for specific laboratory abnormalities when a specific condition is suspected.

* Denotes an Optional Analyte

MS/MS: ACMG Primary Targets: Amino Acids

Argininosuccinic aciduria (ASA)

Argininosuccinate (ASA)

Argininosuccinate / Arginine Ratio (ASA / ARG)

Citrulline (CIT)

Citrulline / Phenylalanine Ratio (CIT / PHE)

Citrullinemia type I (CIT I)

Citrulline (CIT) Citrulline / Phenylalanine Ratio (CIT / PHE)

Homocystinuria (HCY)

Methionine (MET)

Methionine / Phenylalanine Ratio (MET / PHE)

Maple syrup urine disease (MSUD)

Alloisoleucine + Isoleucine + Leucine + Hydroxyproline (AILE + ILE + LEU + OHPRO)

Alloisoleucine + Isoleucine + Leucine + Hydroxyproline / Phenylalanine Ratio ([AILE + ILE + LEU + OHPRO] / PHE)

Alloisoleucine + Isoleucine + Leucine + Hydroxyproline /Alanine ([AILE + ILE + LEU + OHPRO] / ALA)

Valine (VAL)

Valine / Phenylalanine Ratio (VAL/PHE)

Phenylketonuria (PKU)

Phenylalanine (PHE) Phenylalanine / Tyrosine Ratio (PHE / TYR)

Tyrosinemia type I (TYR I)

Succinylacetone (SUAC)

Tyrosine (TYR)*



MS/MS: ACMG Primary Targets: Fatty Acid Oxidase

Carnitine uptake defect (CUD)

Acetylcarnitine (C2)

Carnitine.free (C0)

Carnitine.free + Acetylcarnitine + Propionylcarnitine + Palmitoylcarnitine + Oleylcarnitine + Stearoylcarnitine /Citrulline Ratio ([C0 + C2 + C3 + C16 + C18:1 + C18] / CIT)

Linoleoylcarnitine (C18:2)*

Oleylcarnitine (C18:1)*

Palmitoylcarnitine (C16)*

Stearoylcarnitine (C18)*

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD)

Hydroxydecenoylcarnitine (C10:1OH)*

Hydroxydodecanoylcarnitine (C12OH)*

Hydroxydodecenoylcarnitine (C12:10H)*

Hydroxylinoleoylcarnitine (C18:2OH)

Hydroxyoleylcarnitine (C18:1OH)

Hydroxypalmitoleylcarnitine (C16:1OH)

Hydroxypalmitoylcarnitine (C16OH)

Hydroxypalmitoylcarnitine / Palmitoylcarnitine Ratio (C16OH / C16)

Hydroxytetradecadienylcarnitine (C14:2OH)*

Hydroxytetradecanoylcarnitine (C14OH)

Hydroxytetradecenoylcarnitine (C14:10H)*

Linoleoylcarnitine (C18:2)*

Oleylcarnitine (C18:1)*

Palmitoleylcarnitine (C16:1)*

Palmitoylcarnitine (C16)

Stearoylcarnitine (C18)*

Stearoylcarnitine / Propionylcarnitine Ratio (C18 / C3)*

Tetradecenoylcarnitine (C14:1)*

Medium-chain acyl-CoA dehydrogenase deficiency (MCAD)

Decanoylcarnitine (C10) Decenoylcarnitine (C10:1) Hexanoylcarnitine (C6)* Octanoylcarnitine (C8) Octanoylcarnitine / Acetylcarnitine Ratio (C8 / C2) Octanoylcarnitine / Decanoylcarnitine Ratio (C8 / C10)*



Trifunctional protein deficiency (TFP)

Hydroxydecenoylcarnitine (C10:10H)* Hydroxydodecanoylcarnitine (C12OH)* Hydroxydodecenoylcarnitine (C12:10H)* Hydroxylinoleoylcarnitine (C18:2OH) Hydroxyoleylcarnitine (C18:10H) Hydroxypalmitoleylcarnitine (C16:10H) Hydroxypalmitoylcarnitine (C16OH) Hydroxypalmitoylcarnitine / Palmitoylcarnitine Ratio (C16OH / C16) Hydroxytetradecadienylcarnitine (C14:2OH)* Hydroxytetradecanoylcarnitine (C14OH) Hydroxytetradecenoylcarnitine (C14:10H)* Linoleoylcarnitine (C18:2)* Olevlcarnitine (C18:1)* Palmitoleylcarnitine (C16:1)* Palmitoylcarnitine (C16) Stearoylcarnitine (C18)* Stearoylcarnitine / Propionylcarnitine Ratio (C18 / C3)* Tetradecenoylcarnitine (C14:1)*

Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)

Dodecanoylcarnitine (C12)* Dodecenoylcarnitine (C12:1)* Palmitoleylcarnitine (C16:1)* Palmitoylcarnitine (C16) Tetradecadienoylcarnitine (C14:2) Tetradecanoylcarnitine (C14) Tetradecenoylcarnitine (C14:1) Tetradecenoylcarnitine / Palmitoylcarnitine Ratio (C14:1 / C16) Tetradecenoylcarnitine / Acetylcarnitine Ratio (C14:1 / C12:1)*

MS/MS: ACMG Primary Targets: Organic Acids

3-Hydroxy-3-methylglutaric aciduria (HMG)

Hydroxyisovalerylcarnitine (C5OH) Hydroxyisovalerylcarnitine / Carnitine.free Ratio (C5OH / C0)* Hydroxyisovalerylcarnitine / Octanoylcarnitine Ratio (C50H / C8) Methylglutarylcarnitine (C6DC)



3-Methylcrotonyl-CoA carboxylase deficiency (3MCC)

Hydroxyisovalerylcarnitine (C5OH)

Hydroxyisovalerylcarnitine / Carnitine.free Ratio (C5OH / C0)*

Hydroxyisovalerylcarnitine / Octanoylcarnitine Ratio (C50H / C8)

beta-Ketothiolase deficiency (BKT)

Hydroxyisovalerylcarnitine (C5OH) Hydroxyisovalerylcarnitine / Carnitine.free Ratio (C5OH / C0)* Hydroxyisovalerylcarnitine / Octanoylcarnitine Ratio (C50H / C8) Tiglylcarnitine (C5:1)

Glutaric acidemia type I (GA I)

Glutarylcarnitine + Hydroxydecanoylcarnitine (C5DC + C10OH)

Glutarylcarnitine + Hydroxydecanoylcarnitine / Hydroxyisovalerylcarnitine Ratio (C5DC + C10OH / C5OH)

Glutarylcarnitine + Hydroxydecanoylcarnitine / Octanoylcarnitine Ratio (C5DC + C10OH / C8)

Glutarylcarnitine + Hydroxydecanoylcarnitine / Palmitoylcarnitine Ratio (C5DC + C10OH / C16)

Isovaleric acidemia (IVA)

Isovalerylcarnitine + Methylbutyrylcarnitine (C5) Isovalerylcarnitine + Methylbutyrylcarnitine / Acetylcarnitine Ratio (C5 / C2) Isovalerylcarnitine + Methylbutyrylcarnitine / Carnitine.free Ratio (C5 / C0) Isovalerylcarnitine + Methylbutyrylcarnitine / Propionylcarnitine Ratio (C5 / C3)

Methylmalonic acidemia (CBL A)

Methylmalonylcarnitine (C4DC)*

Methylmalonylcarnitine (C4DC)*

Methylmalonylcarnitine / Hydroxyisovalerylcarnitine Ratio (C4DC / C5OH)*

Methylmalonylcarnitine / Hydroxyisovalerylcarnitine Ratio (C4DC / C5OH)*

Propionylcarnitine (C3)

Propionylcarnitine (C3)

Propionylcarnitine / Acetylcarnitine Ratio (C3 / C2)

Propionylcarnitine / Acetylcarnitine Ratio (C3 / C2)

Propionylcarnitine / Carnitine.free Ratio (C3 / C0)*

Propionylcarnitine / Carnitine.free Ratio (C3 / C0)*

Propionylcarnitine / Palmitoylcarnitine Ratio (C3 / C16)*

Propionylcarnitine / Palmitoylcarnitine Ratio (C3 / C16)*



Multiple carboxylase deficiency (MCD)

Hydroxyisovalerylcarnitine (C5OH) Hydroxyisovalerylcarnitine / Carnitine.free Ratio (C5OH / C0)* Hydroxyisovalerylcarnitine / Octanoylcarnitine Ratio (C50H / C8) Propionylcarnitine (C3)* Propionylcarnitine / Acetylcarnitine Ratio (C3 / C2) Propionylcarnitine / Carnitine.free Ratio (C3 / C0)* Propionylcarnitine / Palmitoylcarnitine Ratio (C3 / C16)*

Propionic acidemia (PROP)

Carnitine.free (C0) Propionylcarnitine (C3) Propionylcarnitine / Acetylcarnitine Ratio (C3 / C2) Propionylcarnitine / Carnitine.free Ratio (C3 / C0)* Propionylcarnitine / Palmitoylcarnitine Ratio (C3 / C16)*

MS/MS: ACMG Secondary Conditions: Amino Acids

Argininemia (ARG)

Arginine (ARG)

Citrullinemia type II (CIT II)

Arginine (ARG)* Citrulline (CIT) Citrulline / Phenylalanine Ratio (CIT / PHE) Threonine (THR)*

Disorders of biopterin biosynthesis (BIOPT-BIO)

Phenylalanine (PHE)

Phenylalanine / Tyrosine Ratio (PHE / TYR)

Disorders of biopterin regeneration (BIOPT-REG)

Phenylalanine (PHE) Phenylalanine / Tyrosine Ratio (PHE / TYR)

Hypermethioninemia (MET)

Methionine (MET)

Methionine / Phenylalanine Ratio (MET / PHE)

Hyperphenylalaninemia (variant, benign) (H-PHE)

Phenylalanine (PHE)

Phenylalanine / Tyrosine Ratio (PHE / TYR)

Survey of the second

Tyrosinemia type II (TYR II)

Tyrosine (TYR)

Tyrosinemia type III (TYR III)

Tyrosine (TYR)

MS/MS: ACMG Secondary Conditions: Fatty Acid Oxidase

2,4-Dienoyl-CoA reductase deficiency (DE RED)

Decadienoylcarnitine (C10:2)

Carnitine palmitoyltransferase I deficiency (CPT I)

- Carnitine.free (C0)
- Carnitine.free / Palmitoylcarnitine+Stearoylcarnitine Ratio (C0 / [C16 + C18])

Carnitine.free / Palmitoylcarnitine Ratio (C0 / C16)*

Carnitine.free / Stearoylcarnitine Ratio (C0 / C18)*

Linoleoylcarnitine (C18:2)

Oleylcarnitine (C18:1)

Palmitoylcarnitine (C16)

Stearoylcarnitine (C18)

Carnitine palmitoyltransferase II deficiency (CPT II)

Carnitine.free / Palmitoylcarnitine+Stearoylcarnitine Ratio (C0 / [C16 + C18])*

Linoleoylcarnitine (C18:2)

Oleylcarnitine (C18:1)

Palmitoleylcarnitine (C16:1)*

Palmitoylcarnitine (C16)

Stearoylcarnitine (C18)

Tetradecanoylcarnitine (C14)*

Carnitine-acylcarnitine translocase deficiency (CACT)

Carnitine.free / Palmitoylcarnitine+Stearoylcarnitine Ratio (C0 / [C16 + C18])* Linoleoylcarnitine (C18:2) Oleylcarnitine (C18:1) Palmitoleylcarnitine (C16:1)* Palmitoylcarnitine (C16) Stearoylcarnitine (C18) Tetradecanoylcarnitine (C14)*



Glutaric acidemia type II (GA II)

Butyrylcarnitine + Isobutyrylcarnitine (C4) Butyrylcarnitine + Isobutyrylcarnitine / Acetylcarnitine Ratio (C4 / C2) Butyrylcarnitine + Isobutyrylcarnitine / Propionylcarnitine Ratio (C4 / C3) Decanoylcarnitine (C10) Decenoylcarnitine (C10:1) Glutarylcarnitine + Hydroxydecanoylcarnitine (C5DC + C10OH) Glutarylcarnitine + Hydroxydecanoylcarnitine / Hydroxyisovalerylcarnitine Ratio (C5DC + C10OH / C5OH) Hexanoylcarnitine (C6)* Isovalerylcarnitine + Methylbutyrylcarnitine (C5) Isovalerylcarnitine + Methylbutyrylcarnitine / Acetylcarnitine Ratio (C5 / C2) Isovalerylcarnitine + Methylbutyrylcarnitine / Carnitine.free Ratio (C5 / C2) Isovalerylcarnitine + Methylbutyrylcarnitine / Propionylcarnitine Ratio (C5 / C3) Octanoylcarnitine (C8)

Medium-chain ketoacyl-CoA thiolase deficiency (MCKAT)

Decanoylcarnitine (C10)* Decenoylcarnitine (C10:1)* Hydroxydecenoylcarnitine (C10:1OH)* Hydroxyhexanoylcarnitine (C6OH) Hydroxyoctanoylcarnitine + Malonylcarnitine (C8OH + C3DC) Hydroxyoctanoylcarnitine + Malonylcarnitine / Decanoylcarnitine Ratio (C8OH + C3DC / C10) Octanoylcarnitine (C8) Octanoylcarnitine / Acetylcarnitine Ratio (C8 / C2) Octanoylcarnitine / Decanoylcarnitine Ratio (C8 / C10)* Octenoylcarnitine (C8:1)*

Short-chain acyl-CoA dehydrogenase deficiency (SCAD)

Butyrylcarnitine + Isobutyrylcarnitine (C4) Butyrylcarnitine + Isobutyrylcarnitine / Acetylcarnitine Ratio (C4 / C2) Butyrylcarnitine + Isobutyrylcarnitine / Octanoylcarnitine Ratio (C4 / C3) Butyrylcarnitine + Isobutyrylcarnitine / Propionylcarnitine Ratio (C4 / C3)

Short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency (SCHAD)

Acetylcarnitine (C2)* Hydroxybutyrylcarnitine (C4OH) Hydroxyhexanoylcarnitine (C6OH)



MS/MS: ACMG Secondary Conditions: Organic Acids

2-Methyl-3-hydroxybutyric aciduria (2M3HBA)

Hydroxyisovalerylcarnitine (C5OH) Hydroxyisovalerylcarnitine / Carnitine.free Ratio (C5OH / C0) Hydroxyisovalerylcarnitine / Octanoylcarnitine Ratio (C50H / C8) Tiglylcarnitine (C5:1)

2-Methylbutyrylglycinuria (2MBG)

Isovalerylcarnitine + Methylbutyrylcarnitine (C5) Isovalerylcarnitine + Methylbutyrylcarnitine / Acetylcarnitine Ratio (C5 / C2) Isovalerylcarnitine + Methylbutyrylcarnitine / Carnitine.free Ratio (C5 / C0) Isovalerylcarnitine + Methylbutyrylcarnitine / Propionylcarnitine Ratio (C5 / C3)

3-Methylglutaconic aciduria (3MGA)

Hydroxyisovalerylcarnitine (C5OH) Hydroxyisovalerylcarnitine / Carnitine.free Ratio (C5OH / C0) Hydroxyisovalerylcarnitine / Octanoylcarnitine Ratio (C50H / C8)

Isobutyrylglycinuria (IBD)

Butyrylcarnitine + Isobutyrylcarnitine (C4)

Butyrylcarnitine + Isobutyrylcarnitine / Acetylcarnitine Ratio (C4 / C2)

Butyrylcarnitine + Isobutyrylcarnitine / Octanoylcarnitine Ratio (C4 / C8)

Butyrylcarnitine + Isobutyrylcarnitine / Propionylcarnitine Ratio (C4 / C3)

Malonic acidemia (MAL)

Hydroxyoctanoylcarnitine + Malonylcarnitine (C8OH + C3DC)

Hydroxyoctanoylcarnitine + Malonylcarnitine / Decanoylcarnitine Ratio (C8OH + C3DC / C10)

Methylmalonic aciduria and homocystinuria (CBL C)

Methionine (MET)* Methionine / Phenylalanine Ratio (MET / PHE)* Methylmalonylcarnitine (C4DC)* Methylmalonylcarnitine / Hydroxyisovalerylcarnitine Ratio (C4DC / C5OH)* Propionylcarnitine (C3) Propionylcarnitine / Acetylcarnitine Ratio (C3 / C2) Propionylcarnitine / Carnitine.free Ratio (C3 / C0)* Propionylcarnitine / Methionine Ratio (C3 / MET)* Propionylcarnitine / Palmitoylcarnitine Ratio (C3 / C16)*

MS/MS: Other Conditions: Amino Acids



Carbamoyltransferase deficiency (CPS)

Citrulline (CIT)*

Citrulline / Phenylalanine Ratio (CIT / PHE)*

Girate atrophy of the retina (Hyper ORN)

Asparagine + Ornithine (ASN + ORN)

Histidinemia (HIS)

Histidine (HIS)

Homocystinuria-megaloblastic anemia (CBL G)

Methionine (MET)

Methionine / Phenylalanine Ratio (MET / PHE)

Hydroxyprolinemia (OH PRO)

Alloisoleucine + Isoleucine + Leucine + Hydroxyproline (AILE + ILE + LEU + OHPRO)

Alloisoleucine + Isoleucine + Leucine + Hydroxyproline / Phenylalanine Ratio ([AILE + ILE + LEU + OHPRO] / PHE)

Alloisoleucine + Isoleucine + Leucine + Hydroxyproline /Alanine ([AILE + ILE + LEU + OHPRO] / ALA)

Hyperlysinemia (Hyper LYS)

Lysine (LYS)

Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome (HHH)

Asparagine + Ornithine (ASN + ORN)*

Homocitrulline (HOMOCIT)

Methylcobalamin deficiency (CBL E)

Methionine (MET)

Methionine / Phenylalanine Ratio (MET / PHE)

Methylene tetrahydrofolate reductase deficiency (MTHFR)

Methionine (MET)

Methionine / Phenylalanine Ratio (MET / PHE)

Nonketotic hyperglycinemia (glycine encephalopathy) (NKHG)

Glycine (GLY)

Ornithine transcarbamylase deficiency (OTC)

Citrulline (CIT)*

Citrulline / Phenylalanine Ratio (CIT / PHE)*

Pyroglutamic acidemia (OXO PRO)

Oxoproline + Pipecolate (OXOPRO + PIPA)



Pyruvate carboxylase deficiency (PC)

Alanine + Beta Alanine + Sarcosine (ALA + BALA + SARC)*

Citrulline (CIT)

Citrulline / Phenylalanine Ratio (CIT / PHE)

Lysine (LYS)*

Proline (PRO)*

Valinemia (Hyper VAL)

Valine (VAL)

Valine / Phenylalanine Ratio (VAL/PHE)

MS/MS: Other Conditions: Fatty Acid Oxidase

Maternal carnitine uptake defect (CUD (mat))

Carnitine.free (C0)

Carnitine.free + Acetylcarnitine + Propionylcarnitine + Palmitoylcarnitine + Oleylcarnitine + Stearoylcarnitine /Citrulline Ratio ([C0 + C2 + C3 + C16 + C18:1 + C18] / CIT) Homocitrulline (HOMOCIT)*

MS/MS: Other Conditions: Organic Acids

Ethylmalonic encephalopathy (EE)

Butyrylcarnitine + Isobutyrylcarnitine (C4) Butyrylcarnitine + Isobutyrylcarnitine / Acetylcarnitine Ratio (C4 / C2) Butyrylcarnitine + Isobutyrylcarnitine / Propionylcarnitine Ratio (C4 / C3) Formiminoglutamic acid (FIGLU) Isovalerylcarnitine + Methylbutyrylcarnitine (C5) Isovalerylcarnitine + Methylbutyrylcarnitine / Acetylcarnitine Ratio (C5 / C2) Isovalerylcarnitine + Methylbutyrylcarnitine / Carnitine.free Ratio (C5 / C0) Tiglylcarnitine (C5:1)

Formiminoglutamic acidemia (FIGLU)

Homocitrulline (HOMOCIT)*

Propionylcarnitine / Palmitoylcarnitine Ratio (C3 / C16)

Maternal 3-Methylcrotonyl-CoA carboxylase deficiency (3MCC (mat))

Carnitine.free (C0)*

 $\label{eq:carnitine} Carnitine + Propionylcarnitine + Palmitoylcarnitine + Oleylcarnitine + Stearoylcarnitine /Citrulline Ratio ([C0 + C2 + C3 + C16 + C18:1 + C18] / CIT)*$

Hexanoylcarnitine (C6)

Homocitrulline (HOMOCIT)*

Hydroxybutyrylcarnitine (C4OH)

Hydroxyisovalerylcarnitine (C5OH)



Maternal glutaric acidemia type I (GA I (mat))

Carnitine.free (C0)

Carnitine.free + Acetylcarnitine + Propionylcarnitine + Palmitoylcarnitine + Oleylcarnitine + Stearoylcarnitine /Citrulline Ratio ([C0 + C2 + C3 + C16 + C18:1 + C18] / CIT)

Glutarylcarnitine + Hydroxydecanoylcarnitine (C5DC + C10OH)*

Glutarylcarnitine + Hydroxydecanoylcarnitine /Butyrylcarnitine + Isobutyrylcarnitine Ratio (C5DC + C10OH / C4)

Hydroxydecenoylcarnitine (C10:1OH)*

Methylmalonylcarnitine / Hydroxyisovalerylcarnitine Ratio (C4DC / C5OH)*

Primary lactic acidemia (various types) (LACTIC)

Alanine + Beta Alanine + Sarcosine (ALA + BALA + SARC)*

Proline (PRO)*

Succinyl-CoA ligase deficiency (SUCLA2)

Decanoylcarnitine (C10)

Decenoylcarnitine (C10:1)

Propenoylcarnitine (C3:1)

Propionylcarnitine / Acetylcarnitine Ratio (C3 / C2)*

Propionylcarnitine / Carnitine.free Ratio (C3 / C0)*

Propionylcarnitine / Methionine Ratio (C3 / MET)*

HERVIN CONTRACT

MS/MS Analytes to Conditions Mapping

The MS/MS Analyte to Condition Mapping report lists the conditions or disorders that are suggested by an abnormal analyte or laboratory measurements (listed in boldface). Final diagnosis depends on confirmatory testing and less common conditions are marked as optional. The mapping of abnormal analytes to specific conditions is not precise and this listing is intended to guide further investigation of the cause of the laboratory abnormality.

* Denotes an Optional Condition

MS/MS: Amino Acids

Arginine (ARG)

Argininemia (ARG)

Citrullinemia type II (CIT II)*

Argininosuccinate (ASA)

Argininosuccinic aciduria (ASA)

Citrulline (CIT)

Argininosuccinic aciduria (ASA) Carbamoyltransferase deficiency (CPS)* Citrullinemia type I (CIT I) Citrullinemia type II (CIT II) Ornithine transcarbamylase deficiency (OTC)* Pyruvate carboxylase deficiency (PC)

Glycine (GLY)

Nonketotic hyperglycinemia (glycine encephalopathy) (NKHG)

Histidine (HIS)

Histidinemia (HIS)

Homocitrulline (HOMOCIT)

Formiminoglutamic acidemia (FIGLU)*

Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome (HHH)

Maternal 3-Methylcrotonyl-CoA carboxylase deficiency (3MCC (mat))*

Maternal carnitine uptake defect (CUD (mat))*

Lysine (LYS)

Hyperlysinemia (Hyper LYS)

Pyruvate carboxylase deficiency (PC)*

Methionine (MET)

Homocystinuria (HCY) Homocystinuria-megaloblastic anemia (CBL G) Hypermethioninemia (MET) Methylcobalamin deficiency (CBL E) Methylene tetrahydrofolate reductase deficiency (MTHFR) Methylmalonic aciduria and homocystinuria (CBL C)*

Phenylalanine (PHE)

Disorders of biopterin biosynthesis (BIOPT-BIO) Disorders of biopterin regeneration (BIOPT-REG) Hyperphenylalaninemia (variant, benign) (H-PHE) Phenylketonuria (PKU)

Proline (PRO)

Primary lactic acidemia (various types) (LACTIC)* Pyruvate carboxylase deficiency (PC)*

Succinylacetone (SUAC)

Tyrosinemia type I (TYR I)

Threonine (THR)

Citrullinemia type II (CIT II)*

Tyrosine (TYR)

Tyrosinemia type I (TYR I)*

Tyrosinemia type II (TYR II)

Tyrosinemia type III (TYR III)

Valine (VAL)

Maple syrup urine disease (MSUD)

Valinemia (Hyper VAL)

MS/MS: Amino Acids CALCULATED RATIO



Alloisoleucine + Isoleucine + Leucine + Hydroxyproline /Alanine ([AILE + ILE + LEU + OHPRO] / ALA)

Hydroxyprolinemia (OH PRO)

Maple syrup urine disease (MSUD)

Alloisoleucine + Isoleucine + Leucine + Hydroxyproline / Phenylalanine Ratio ([AILE + ILE + LEU + OHPRO] / PHE)

Hydroxyprolinemia (OH PRO)

Maple syrup urine disease (MSUD)

Alloisoleucine + Isoleucine + Leucine + Hydroxyproline (AILE + ILE + LEU + OHPRO)

Hydroxyprolinemia (OH PRO)

Maple syrup urine disease (MSUD)

Alanine + Beta Alanine + Sarcosine (ALA + BALA + SARC)

Primary lactic acidemia (various types) (LACTIC)*

Pyruvate carboxylase deficiency (PC)*

Argininosuccinate / Arginine Ratio (ASA / ARG)

Argininosuccinic aciduria (ASA)

Asparagine + Ornithine (ASN + ORN)

Girate atrophy of the retina (Hyper ORN)

Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome (HHH)*

Citrulline / Phenylalanine Ratio (CIT / PHE)

Argininosuccinic aciduria (ASA) Carbamoyltransferase deficiency (CPS)* Citrullinemia type I (CIT I) Citrullinemia type II (CIT II) Ornithine transcarbamylase deficiency (OTC)* Pyruvate carboxylase deficiency (PC)

Methionine / Phenylalanine Ratio (MET / PHE)

Homocystinuria (HCY) Homocystinuria-megaloblastic anemia (CBL G) Hypermethioninemia (MET) Methylcobalamin deficiency (CBL E) Methylene tetrahydrofolate reductase deficiency (MTHFR) Methylmalonic aciduria and homocystinuria (CBL C)*



Oxoproline + Pipecolate (OXOPRO + PIPA)

Pyroglutamic acidemia (OXO PRO)

Phenylalanine / Tyrosine Ratio (PHE / TYR)

Disorders of biopterin biosynthesis (BIOPT-BIO) Disorders of biopterin regeneration (BIOPT-REG) Hyperphenylalaninemia (variant, benign) (H-PHE) Phenylketonuria (PKU)

Valine / Phenylalanine Ratio (VAL/PHE)

Maple syrup urine disease (MSUD)

Valinemia (Hyper VAL)

MS/MS: Acyl-Carnitine

Octenoylcarnitine (C8:1)

Medium-chain ketoacyl-CoA thiolase deficiency (MCKAT)*

MS/MS: Fatty Acid Oxidase

Carnitine.free (C0)

Carnitine palmitoyltransferase I deficiency (CPT I) Carnitine uptake defect (CUD) Maternal 3-Methylcrotonyl-CoA carboxylase deficiency (3MCC (mat))* Maternal carnitine uptake defect (CUD (mat)) Maternal glutaric acidemia type I (GA I (mat)) Propionic acidemia (PROP)

Decanoylcarnitine (C10)

Glutaric acidemia type II (GA II) Medium-chain acyl-CoA dehydrogenase deficiency (MCAD) Medium-chain ketoacyl-CoA thiolase deficiency (MCKAT)* Succinyl-CoA ligase deficiency (SUCLA2)



Decenoylcarnitine (C10:1)

Glutaric acidemia type II (GA II) Medium-chain acyl-CoA dehydrogenase deficiency (MCAD) Medium-chain ketoacyl-CoA thiolase deficiency (MCKAT)* Succinyl-CoA ligase deficiency (SUCLA2)

Hydroxydecenoylcarnitine (C10:10H)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD)* Maternal glutaric acidemia type I (GA I (mat))* Medium-chain ketoacyl-CoA thiolase deficiency (MCKAT)* Trifunctional protein deficiency (TFP)*

Decadienoylcarnitine (C10:2)

2,4-Dienoyl-CoA reductase deficiency (DE RED)

Dodecanoylcarnitine (C12)

Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)*

Dodecenoylcarnitine (C12:1)

Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)*

Hydroxydodecenoylcarnitine (C12:10H)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD)* Trifunctional protein deficiency (TFP)*

Hydroxydodecanoylcarnitine (C12OH)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD)* Trifunctional protein deficiency (TFP)*

Tetradecanoylcarnitine (C14)

Carnitine palmitoyltransferase II deficiency (CPT II)* Carnitine-acylcarnitine translocase deficiency (CACT)* Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)

Tetradecenoylcarnitine (C14:1)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD)* Trifunctional protein deficiency (TFP)* Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)

A DERVICES IN

Hydroxytetradecenoylcarnitine (C14:10H)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD)* Trifunctional protein deficiency (TFP)*

Tetradecadienoylcarnitine (C14:2)

Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)

Hydroxytetradecadienylcarnitine (C14:2OH)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD)* Trifunctional protein deficiency (TFP)*

Hydroxytetradecanoylcarnitine (C14OH)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD) Trifunctional protein deficiency (TFP)

Palmitoylcarnitine (C16)

Carnitine palmitoyltransferase I deficiency (CPT I) Carnitine palmitoyltransferase II deficiency (CPT II) Carnitine uptake defect (CUD)* Carnitine-acylcarnitine translocase deficiency (CACT) Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD) Trifunctional protein deficiency (TFP) Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)

Palmitoleylcarnitine (C16:1)

Carnitine palmitoyltransferase II deficiency (CPT II)* Carnitine-acylcarnitine translocase deficiency (CACT)* Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD)* Trifunctional protein deficiency (TFP)* Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)*

Hydroxypalmitoleylcarnitine (C16:10H)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD) Trifunctional protein deficiency (TFP)

Hydroxypalmitoylcarnitine (C16OH)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD) Trifunctional protein deficiency (TFP)



Stearoylcarnitine (C18)

Carnitine palmitoyltransferase I deficiency (CPT I) Carnitine palmitoyltransferase II deficiency (CPT II) Carnitine uptake defect (CUD)* Carnitine-acylcarnitine translocase deficiency (CACT) Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD)* Trifunctional protein deficiency (TFP)*

Oleylcarnitine (C18:1)

Carnitine palmitoyltransferase I deficiency (CPT I) Carnitine palmitoyltransferase II deficiency (CPT II) Carnitine uptake defect (CUD)* Carnitine-acylcarnitine translocase deficiency (CACT) Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD)* Trifunctional protein deficiency (TFP)*

Hydroxyoleylcarnitine (C18:10H)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD) Trifunctional protein deficiency (TFP)

Linoleoylcarnitine (C18:2)

Carnitine palmitoyltransferase I deficiency (CPT I) Carnitine palmitoyltransferase II deficiency (CPT II) Carnitine uptake defect (CUD)* Carnitine-acylcarnitine translocase deficiency (CACT) Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD)* Trifunctional protein deficiency (TFP)*

Hydroxylinoleoylcarnitine (C18:2OH)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD) Trifunctional protein deficiency (TFP)

Hydroxybutyrylcarnitine (C4OH)

Maternal 3-Methylcrotonyl-CoA carboxylase deficiency (3MCC (mat)) Short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency (SCHAD)

Hexanoylcarnitine (C6)

Glutaric acidemia type II (GA II)* Maternal 3-Methylcrotonyl-CoA carboxylase deficiency (3MCC (mat)) Medium-chain acyl-CoA dehydrogenase deficiency (MCAD)*

Hydroxyhexanoylcarnitine (C6OH)

Medium-chain ketoacyl-CoA thiolase deficiency (MCKAT) Short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency (SCHAD)

Octanoylcarnitine (C8)

Glutaric acidemia type II (GA II)

Medium-chain acyl-CoA dehydrogenase deficiency (MCAD)

Medium-chain ketoacyl-CoA thiolase deficiency (MCKAT)

MS/MS: Fatty Acid Oxidase CALCULATED RATIO

Carnitine.free + Acetylcarnitine + Propionylcarnitine + Palmitoylcarnitine + Oleylcarnitine + Stearoylcarnitine /Citrulline Ratio ([C0 + C2 + C3 + C16 + C18:1 + C18] / CIT)

Carnitine uptake defect (CUD)

Maternal 3-Methylcrotonyl-CoA carboxylase deficiency (3MCC (mat))*

Maternal carnitine uptake defect (CUD (mat))

Maternal glutaric acidemia type I (GA I (mat))

Carnitine.free / Palmitoylcarnitine+Stearoylcarnitine Ratio (C0 / [C16 + C18])

Carnitine palmitoyltransferase I deficiency (CPT I)

Carnitine palmitoyltransferase II deficiency (CPT II)*

Carnitine-acylcarnitine translocase deficiency (CACT)*

Carnitine.free / Palmitoylcarnitine Ratio (C0 / C16)

Carnitine palmitoyltransferase I deficiency (CPT I)*

Carnitine.free / Stearoylcarnitine Ratio (C0 / C18)

Carnitine palmitoyltransferase I deficiency (CPT I)*

Tetradecenoylcarnitine / Dodecenoylcarnitine Ratio (C14:1 / C12:1)

Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)*

Tetradecenoylcarnitine / Palmitoylcarnitine Ratio (C14:1 / C16)

Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)



Tetradecenoylcarnitine / Acetylcarnitine Ratio (C14:1 / C2)

Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)

Hydroxypalmitoylcarnitine / Palmitoylcarnitine Ratio (C16OH / C16)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD) Trifunctional protein deficiency (TFP)

Stearoylcarnitine / Propionylcarnitine Ratio (C18 / C3)

Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency (LCHAD)* Trifunctional protein deficiency (TFP)*

Octanoylcarnitine / Decanoylcarnitine Ratio (C8 / C10)

Medium-chain acyl-CoA dehydrogenase deficiency (MCAD)* Medium-chain ketoacyl-CoA thiolase deficiency (MCKAT)*

Octanoylcarnitine / Acetylcarnitine Ratio (C8 / C2)

Glutaric acidemia type II (GA II) Medium-chain acyl-CoA dehydrogenase deficiency (MCAD) Medium-chain ketoacyl-CoA thiolase deficiency (MCKAT)

MS/MS: Fatty Acid Oxidase-Organic Acids

Acetylcarnitine (C2)

Carnitine uptake defect (CUD)

Short-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency (SCHAD)*

MS/MS: Fatty Acid Oxidase-Organic Acids CALCULATED RATIO

Butyrylcarnitine + Isobutyrylcarnitine (C4)

Ethylmalonic encephalopathy (EE)

Glutaric acidemia type II (GA II)

Isobutyrylglycinuria (IBD)

Short-chain acyl-CoA dehydrogenase deficiency (SCAD)

Butyrylcarnitine + Isobutyrylcarnitine / Acetylcarnitine Ratio (C4 / C2)

Ethylmalonic encephalopathy (EE)

Glutaric acidemia type II (GA II)

Isobutyrylglycinuria (IBD)

Short-chain acyl-CoA dehydrogenase deficiency (SCAD)



Butyrylcarnitine + Isobutyrylcarnitine / Propionylcarnitine Ratio (C4 / C3)

Ethylmalonic encephalopathy (EE)

Glutaric acidemia type II (GA II)

Isobutyrylglycinuria (IBD)

Short-chain acyl-CoA dehydrogenase deficiency (SCAD)

Butyrylcarnitine + Isobutyrylcarnitine / Octanoylcarnitine Ratio (C4 / C8)

Isobutyrylglycinuria (IBD)

Short-chain acyl-CoA dehydrogenase deficiency (SCAD)

Glutarylcarnitine + Hydroxydecanoylcarnitine (C5DC + C10OH)

Glutaric acidemia type I (GA I)

Glutaric acidemia type II (GA II)

Maternal glutaric acidemia type I (GA I (mat))*

Glutarylcarnitine + Hydroxydecanoylcarnitine / Palmitoylcarnitine Ratio (C5DC + C10OH / C16)

Glutaric acidemia type I (GA I)

Glutarylcarnitine + Hydroxydecanoylcarnitine /Butyrylcarnitine + Isobutyrylcarnitine Ratio (C5DC + C10OH / C4)

Maternal glutaric acidemia type I (GA I (mat))

Glutarylcarnitine + Hydroxydecanoylcarnitine / Hydroxyisovalerylcarnitine Ratio (C5DC + C10OH / C5OH)

Glutaric acidemia type I (GA I)

Glutaric acidemia type II (GA II)

Glutarylcarnitine + Hydroxydecanoylcarnitine / Octanoylcarnitine Ratio (C5DC + C10OH / C8)

Glutaric acidemia type I (GA I)

Hydroxyoctanoylcarnitine + Malonylcarnitine (C8OH + C3DC)

Malonic acidemia (MAL)

Medium-chain ketoacyl-CoA thiolase deficiency (MCKAT)

Hydroxyoctanoylcarnitine + Malonylcarnitine / Decanoylcarnitine Ratio (C8OH + C3DC / C10)

Malonic acidemia (MAL)

Medium-chain ketoacyl-CoA thiolase deficiency (MCKAT)

MS/MS: Organic Acids



Propionylcarnitine (C3)

Methylmalonic acidemia (MUT) Methylmalonic acidemia (CBL A) Methylmalonic aciduria and homocystinuria (CBL C) Multiple carboxylase deficiency (MCD)* Propionic acidemia (PROP)

Propenoylcarnitine (C3:1)

Succinyl-CoA ligase deficiency (SUCLA2)

Methylmalonylcarnitine (C4DC)

Methylmalonic acidemia (CBL A)* Methylmalonic acidemia (MUT)* Methylmalonic aciduria and homocystinuria (CBL C)*

Tiglylcarnitine (C5:1)

2-Methyl-3-hydroxybutyric aciduria (2M3HBA) beta-Ketothiolase deficiency (BKT) Ethylmalonic encephalopathy (EE)

Hydroxyisovalerylcarnitine (C5OH)

2-Methyl-3-hydroxybutyric aciduria (2M3HBA)
3-Hydroxy-3-methylglutaric aciduria (HMG)
3-Methylcrotonyl-CoA carboxylase deficiency (3MCC)
3-Methylglutaconic aciduria (3MGA)
beta-Ketothiolase deficiency (BKT)
Maternal 3-Methylcrotonyl-CoA carboxylase deficiency (3MCC (mat))
Multiple carboxylase deficiency (MCD)

Methylglutarylcarnitine (C6DC)

3-Hydroxy-3-methylglutaric aciduria (HMG)

Formiminoglutamic acid (FIGLU)

Ethylmalonic encephalopathy (EE)

MS/MS: Organic Acids CALCULATED RATIO



Propionylcarnitine / Carnitine.free Ratio (C3 / C0)

Methylmalonic acidemia (MUT)* Methylmalonic acidemia (CBL A)* Methylmalonic aciduria and homocystinuria (CBL C)* Multiple carboxylase deficiency (MCD)* Propionic acidemia (PROP)* Succinyl-CoA ligase deficiency (SUCLA2)*

Propionylcarnitine / Palmitoylcarnitine Ratio (C3 / C16)

Formiminoglutamic acidemia (FIGLU) Methylmalonic acidemia (CBL A)* Methylmalonic acidemia (MUT)* Methylmalonic aciduria and homocystinuria (CBL C)* Multiple carboxylase deficiency (MCD)* Propionic acidemia (PROP)*

Propionylcarnitine / Acetylcarnitine Ratio (C3 / C2)

Methylmalonic acidemia (MUT) Methylmalonic acidemia (CBL A) Methylmalonic aciduria and homocystinuria (CBL C) Multiple carboxylase deficiency (MCD) Propionic acidemia (PROP) Succinyl-CoA ligase deficiency (SUCLA2)*

Propionylcarnitine / Methionine Ratio (C3 / MET)

Methylmalonic aciduria and homocystinuria (CBL C)* Succinyl-CoA ligase deficiency (SUCLA2)*

Methylmalonylcarnitine / Hydroxyisovalerylcarnitine Ratio (C4DC / C5OH)

Maternal glutaric acidemia type I (GA I (mat))* Methylmalonic acidemia (MUT)* Methylmalonic acidemia (CBL A)* Methylmalonic aciduria and homocystinuria (CBL C)*

Isovalerylcarnitine + Methylbutyrylcarnitine (C5)

2-Methylbutyrylglycinuria (2MBG)

Ethylmalonic encephalopathy (EE)

Glutaric acidemia type II (GA II)

Isovaleric acidemia (IVA)



Isovalerylcarnitine + Methylbutyrylcarnitine / Carnitine.free Ratio (C5 / C0)

2-Methylbutyrylglycinuria (2MBG) Ethylmalonic encephalopathy (EE) Glutaric acidemia type II (GA II) Isovaleric acidemia (IVA)

Isovalerylcarnitine + Methylbutyrylcarnitine / Acetylcarnitine Ratio (C5 / C2)

2-Methylbutyrylglycinuria (2MBG) Ethylmalonic encephalopathy (EE) Glutaric acidemia type II (GA II) Isovaleric acidemia (IVA)

Isovalerylcarnitine + Methylbutyrylcarnitine / Propionylcarnitine Ratio (C5 / C3)

2-Methylbutyrylglycinuria (2MBG) Glutaric acidemia type II (GA II) Isovaleric acidemia (IVA)

Hydroxyisovalerylcarnitine / Octanoylcarnitine Ratio (C50H / C8)

2-Methyl-3-hydroxybutyric aciduria (2M3HBA)

3-Hydroxy-3-methylglutaric aciduria (HMG)

3-Methylcrotonyl-CoA carboxylase deficiency (3MCC)

3-Methylglutaconic aciduria (3MGA)

beta-Ketothiolase deficiency (BKT)

Multiple carboxylase deficiency (MCD)

Hydroxyisovalerylcarnitine / Carnitine.free Ratio (C5OH / C0)

2-Methyl-3-hydroxybutyric aciduria (2M3HBA)
3-Hydroxy-3-methylglutaric aciduria (HMG)*
3-Methylcrotonyl-CoA carboxylase deficiency (3MCC)*
3-Methylglutaconic aciduria (3MGA)
beta-Ketothiolase deficiency (BKT)*
Multiple carboxylase deficiency (MCD)*